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ABSTRACT 
Monica L. Schmidt: Design and Validation of Two Predictive Models for Mortality and 
Readmission Following Surgery in Patients with Liver Cirrhosis 
(Under the direction of Morris Weinberger) 
Cirrhosis is the 12
th
 leading cause of death in the United States. By 2020, it is expected to 
affect more than 1 million Americans. Cirrhosis is a costly, chronic condition requiring frequent 
hospitalizations and unplanned readmissions. Patients with cirrhosis often require routine 
surgeries including hernia repair, coronary artery by-pass surgery and orthopedic hip or knee 
replacements. These procedures present a greater risk of morbidity and mortality for cirrhotic 
patients, including a 8-fold increase in risk of mortality and higher hepatic decompensation after 
surgery. Predicting post-operative mortality prior to surgery or post-operative readmission would 
allow patients and clinicians to make informed decisions that optimize survival and reduce 
readmission costs. Currently, the MELD score is often used, inappropriately, to assess risk of 
procedures in patients with decompensated cirrhosis. However, no models exist that predict 
mortality or readmission among patients with cirrhosis. This study aimed to develop and validate 
two predictive models; one for mortality among all patients with cirrhosis undergoing surgery; 
the other will predict readmission among cirrhosis patients discharged alive after the index 
surgery. Each two model was then compared to the MELD score. The NSQIP Mortality Model 
was significantly better than the MELD score at predicting mortality (p<0.001) and had an area 
under the receiver operating characteristic (AUROC) curve of 0.84. The readmission model was 
also significantly better than the MELD score (p<0.001), with an AUROC of 0.75. Both models 
iv 
provide the basis for developing two decision tools that can assist clinicians and patients in 
making informed decisions that optimize survival and reduce unplanned readmissions.  
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CHAPTER 1. SPECIFIC AIMS 
Liver cirrhosis is a costly chronic condition requiring frequent hospitalizations, often for 
surgery. When undergoing surgery, patients with cirrhosis are at high risk for mortality and 
hepatic decompensation as well as for readmission to the hospital following discharge. 
Predicting their post-operative mortality as well as readmission post-discharge would allow 
patients and clinicians to improve: (1) treatment decision-making for patients and (2) process and 
outcomes of care by having hospitals implement strategies to reduce complications leading to 
readmissions and death. Currently, the Model for End-Stage Liver Disease (MELD) score is 
often used, inappropriately, to assess risk of procedures in patients with decompensated cirrhosis. 
However, no models exist that predict mortality or readmission among patients with cirrhosis.  
The long-term objective of this research is to improve the quality of life for patients with 
cirrhosis. The immediate objective of this study is to develop and validate models that predict 
mortality for patients with cirrhosis undergoing surgery as well as their risk of readmission 
following hospital discharge. Each model will be compared to the MELD. The central hypothesis 
is that we can develop validated models that perform better than the MELD. The rationale for the 
proposed research is that these predictive models will be able to: 1) improve surgical decision 
making and 2) inform allocation of appropriate post-discharge resources within risk-stratified 
discharge plans that reduce readmissions. 
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Aim 1: The Mortality Model  
To develop and validate a mortality predictive model and compare it to the currently used 
MELD score. 
Aim 1a: To develop a model that predicts increased risk of in-hospital mortality after the index 
surgery. 
Based on previous literature, age, gender, body mass index, functional status, 
ethnicity/race, American Surgical Association classification (ASA class), estimated 
glomerular filtration rate, serum albumin, platelet count, white blood cell count, total 
bilirubin, prothrombin time international normalization ratio (INR), emergent surgery, 
surgery type, and specific comorbid conditions will increase the risk of in-hospital 
mortality in patients with cirrhosis after the index surgery. 
Aim 1b: Using results from Aim 1a, validate the mortality predictive model. 
Hypothesis: The predictive model will have an area under the receiving operating 
characteristic curve (AUROC) of at least 0.75 when using cross-validation methods. 
Aim 1c: To compare the mortality model to the MELD score. 
Hypothesis: The predictive model will have significantly greater AUROC than the 
MELD score. 
Aim 2: The Readmission Model  
Aim 2a: To develop a model that predicts the risk of unplanned readmission within 30-days from 
discharge after the index surgery. 
In addition to all variables used in the mortality model, post-operative variables will be 
added to include: pneumonia, sepsis, time on operating table, total time under anesthesia, 
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acute/progressive renal failure, urinary tract infection, ventilator wean time >48 hours 
after surgery, and discharge destination. 
Aim 2b: Using results from Aim 1b, validate the readmission predictive model. 
Hypothesis: The predictive model will have an area under the receiving operating 
characteristic curve (AUROC) of at least 0.75 when using cross-validation methods. 
Aim 2c: To compare the readmission model to the MELD score. 
Hypothesis: The predictive model will have significantly greater AUROC than the 
MELD score. 
 
The two models can inform targeted measures to reduce inpatient mortality and 
readmission within 30 days of the index surgery. The mortality model would be used prior to 
surgery during the consultation between the hepatologist, surgeon, and patient to inform the risk 
associated with surgery. This information could be used to discuss the benefits and risks of 
alternative treatment options (including the decision to undergo surgery). The readmission model 
would be used prior to discharge to help a hospital’s transitional care team provide appropriate 
discharge planning that may mitigate readmission, an increasingly important outcome to 
hospitals given the Centers for Medicare and Medicaid Services (CMS) Hospital Readmissions 
Reductions Program. Either of these models could feed decision support, tools that capitalize on 
increased access to clinical data from electronic medical records. 
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CHAPTER 2. BACKGROUND & STUDY OVERVIEW  
Background 
Cirrhosis is the twelfth-leading cause of death in the United States[1]. By 2020, it is 
expected to affect more than 1 million Americans[2]. Cirrhosis is a costly, chronic condition 
requiring frequent hospitalizations and unplanned readmissions[3, 4]. The average-length stay 
for patients hospitalized with cirrhosis is eight days with a mean charge of $46,663 per stay if 
decompensated[5]. Cumulative one- and five-year risks for readmission were 45% and 83% in a 
study of 200 patients with cirrhosis.[3]. 
Patients with cirrhosis often require routine surgeries to maintain their quality of life. 
Hernia repair, coronary artery by-pass surgery, and orthopedic hip or knee replacements are 
common as these patients age[6]. These procedures present a greater risk of morbidity and 
mortality for cirrhotic patients[6, 7], including an eight-fold increase in risk of mortality[8] and 
increased hepatic decompensation[6, 9]. A patient with liver disease who has any of the 
following conditions is decompensated: ascites (fluid) in the abdominal cavity, hepatic 
encephalopathy (swelling of the brain), portal hypertension, or variceal hemorrhage (bleeding in 
esophagus). Decompensation increases the risk of in-hospital mortality as well as unplanned 
readmissions among those who survive to discharge[10-12].  
 Predicting post-operative mortality prior to surgery would allow patients and clinicians to 
make informed decisions that optimize survival[13]. Patients who die in-hospital after a surgical 
procedure may incur a prolonged stay in acute care. The cost of a prolonged stay would not be 
fully covered if the bundled service payment allows for a short stay in acute care after surgery. 
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Predictive models that allow for preventative services to be delivered to patients at greater risk of 
in-hospital mortality (i.e. prolonged stay) or readmission may mitigate financial losses 
experienced by hospitals under the bundled payment initiative[14, 15]. 
Readmissions are problematic for patients and may represent a problem in the quality of 
care during the index admission or the post-discharge period. The urgency to reduce 
readmissions is fueled by financial penalties imposed on hospitals by the Centers for Medicare 
and Medicaid Services (CMS) for Medicare patients with 30-day readmissions [16, 17]. As the 
cirrhotic population ages, more will have Medicare as their primary payer and expose hospitals 
to the risk for significant financial penalties [17]. Other payers will likely adopt CMS’s financial 
incentives to reduce 30-day readmissions. As CMS begins its bundled payments for care , it will 
be critical to a hospital’s financial health to know the risk of a prolonged stay or complication 
prior to the service provided (e.g., surgical procedure). The ability to predict the risk of 
readmission among those who survive surgery would allow for appropriate discharge 
planning[18].  
Predictive Models in Medicine to Improve the Quality of Care 
 Making decisions using complex information is standard practice in medicine. Clinicians 
are expected to make decisions by evaluating immense quantities of data and, using evidence-
based guidelines, apply those data to a specific patient. For example, when choosing to take a 
patient with cirrhosis to surgery, hepatologists and surgeons consider laboratory, history, social, 
and clinical factors that might impact outcomes[19, 20]. There is a need for a model that can 
deliver an evidence-based, patient-centered risk assessment of the cirrhotic patient to assist with 
this difficult clinical decision.  
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Electronic health records make it more feasible to incorporate patient data into predictive 
models that can give the clinician a quantitative risk score for readmission or mortality[21]. 
Predictive models may assist physicians when making decisions that involve complex patients 
instead of relying solely on their prior experiences[22, 23]. Ultimately, these models can be used 
as the foundation for shared decision-making and targeted discharge planning[24]. In an era 
when population health outcomes are linked to reimbursement, there is a need for predictive 
models to inform decisions and allocate resources [25]. 
The MELD Score 
The Model for End-Stage Liver Disease (MELD) score was originally developed and 
validated to predict mortality in patients with cirrhosis undergoing transjugular intrahepatic 
portosystemic shunt (TIPS) procedures. It was validated with 231 patients undergoing elective 
TIPS procedures to prevent hemorrhage or to treat refractory ascites[26, 27]; 70 patients died 
within 90 days of the procedure. Variables included in the MELD score are serum creatinine, 
total bilirubin, and prothrombin INR as follows: 
MELD Score = (0.957 * ln(serum creatinine) + 0.378 * ln(serum bilirubin) + 1.120 * 
ln(PT INR) + 0.643 ) * 10 (if hemodialysis, value for creatinine is 
automatically set to 4.0) 
 
 Although the MELD score is attractive because it uses objective, commonly available 
laboratory values, there are many weaknesses. First, inter-laboratory variability in creatinine 
measurement causes poor predictive power of the MELD score[28-30]. Replacing creatinine 
with estimated glomerular filtration rate (eGFR) could mitigate this problem by offering more 
robust measures of liver biosynthetic function[31, 32]. Second, there is evidence that sodium, 
albumin, and platelet counts are important predictors of liver function and should be included in 
the predictive model[33-39]. In fact, the MELD score was modified to include sodium in 2006. 
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However, this modified MELD-NA has not been fully accepted [35]. Third, MELD score 
performs poorly when assessing the immediate risk of mortality after surgery. In the largest 
study to date, Teh and colleagues used 772 patients having any major surgical procedure and 
cirrhosis to assess the MELD score as a model for predicting post-surgical mortality [7]. 
Although they found the MELD score to predict 30-day post-surgical mortality with some 
accuracy, it was not accurate zero to 7 days after surgery[7]. Moreover, MELD scores fail to 
include important predictors of mortality such as age [7]. In addition, gender influences the 
MELD score’s ability to predict short-term mortality in patients awaiting transplant[40, 41]. 
Differences in creatinine levels and height between males and females result in increased MELD 
scores for women rather than the severity of liver dysfunction[40, 41]. Finally, the MELD score 
is a poor predictor of mortality in the presence of complications of cirrhosis such as persistent 
ascites and hepatorenal syndrome [28]. These factors limit the usefulness of the MELD. Thus, it 
is critical to develop and validate a predictive model that is robust when predicting post-surgical 
mortality across different ages, genders, and varying degrees of liver dysfunction.  
 Beyond the weakness in using the MELD score to predict mortality, little is known about 
its ability to predict readmissions in patients with decompensated cirrhosis[4]. The only two 
single-site studies to date found that MELD predicted readmission in patients with 
decompensated cirrhosis when controlling for serum sodium, number of medications, gender, 
number of comorbidities, transplant list status, and discharge destination[4, 12]. However, both 
studies were small and had limited generalizability. Therefore, there is a need to develop and 
validate a model to predict hospital readmission for post-surgical patients with either 
compensated or decompensated cirrhosis.   
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Study Overview 
Currently, clinicians use the MELD score to guide surgical treatment decisions [42, 43]. 
To date, there are no valid predictive models to assess risk of mortality or readmission for 
patients with cirrhosis. My dissertation will address this gap in the literature by developing and 
validating two predictive models that will accurately stratify patients with cirrhosis by their risk 
of in-hospital mortality and 30-day readmission after surgery.  
The Proposed Predictive Models: Theory and Selection of the Measures  
 A thorough literature review and discussion with hepatologists and surgeons allowed a 
priori selection of variables for consideration in the predictive models for both in-hospital 
mortality and readmission (Table 1) for common surgical procedures undergone by patients with 
cirrhosis (Table 2).  
Institutional Review Board Approval 
This study has been given an exemption (IRB No. 13-3559) by the Office of Human 
Research Ethics at the University of North Carolina. It is a limited dataset and does not involve 
subject contact. The study was deemed exempt and updated to the American College of 
Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) on November 11, 
2013, and renewal is not required. 
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CHAPTER 3. THE NSQIP MORTALITY MODEL 
Introduction 
 The ability to predict post-operative mortality prior to surgery would allow patients and 
clinicians to make informed decisions that optimize survival[13]. Patients who die in-hospital 
after a surgical procedure may incur a prolonged stay in acute care. The cost of a prolonged stay 
would not be fully covered if the bundled service payment only allows for a short stay in acute 
care after surgery. Predictive models that allow for preventative services to be delivered to 
patients at greater risk of in-hospital mortality (i.e., prolonged stay) may mitigate financial losses 
experienced by hospitals under the bundled payment initiative[14, 15]. This study aimed to 
develop, validate, and compare a mortality model to the MELD score.  
Methods 
Data Source and Sample Selection 
This study used American College of Surgeons (ACS) National Surgical Quality 
Improvement Program (NSQIP) data from 2011–2013[44]. NSQIP is a national voluntary 
program to help hospitals reduce surgical morbidity and mortality. The program offers three 
levels of participation that vary by labor intensity to allow smaller hospitals with limited 
resources to participate. To date, more than 300 hospitals nationwide participate in the 
NSQIP[44]. 
Data are collected through a combination of electronic and manual chart abstraction at 
each site. More than 150 variables are collected on surgical cases. Each year, hospitals rotate 
through 46 eight-day cycles of data collection to capture a random sampling of surgical cases. 
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Included are patients having a major surgery, defined by Current Procedural Terminology (CPT) 
code, during one of the eight-week data collection cycles. Both emergent and non-emergent 
surgeries are captured. Trauma and transplant surgeries are excluded[44, 45].  
Data are collected at the patient level. Pre-, intra-, and post-operative variables are 
collected for each patient. If a patient died prior to discharge, he or she is captured in the 
discharge status variable with an “expired” status[44].  
Identifying Patients with Cirrhosis 
I selected patients with liver disease, defined as having an esophageal hemorrhage or 
ascites as identified by the ACS NSQIP [44]. The ACS NSQIP definition for these variables 
requires a history of liver disease on record concurrent with an esophageal varices or ascites 
diagnosis[44, 45]. For these patients, previously validated laboratory values were used to define 
liver cirrhosis: platelet value of < 140,000/mm
3 
and albumin <3.5 g/dL and prothrombin 
INR>1.5 [45-47]. Finally, patients with disseminated cancer, an outpatient surgery, or a do not 
resuscitate (DNR) order on file, as defined by a variable in the NSQIP, were excluded. This 
resulted in a final cohort of patients with liver cirrhosis (n=4,916).  
Mortality Model Cohort  
 For aims 1a, 1b, and 1c, all patients with cirrhosis were included. After excluding 273 
patients with missing laboratory data, I used variables from the NSQIP to identify patients who 
died while hospitalized and were not discharged after the index surgery (Figure 1). Of those with 
cirrhosis, 608 died while hospitalized and 4,308 were discharged alive. Our final cohort for 
analysis in aims 1a, 1b, and 1c will include patients with laboratory values available to generate 
the MELD score and mortality model (died: n=543) and (n=4,100 discharged alive). 
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Bivariate Analyses 
 Patients with and without an in-hospital death were compared using analysis of variance 
(ANOVA), chi-square analyses, and non-parametric test for trends in ordered variables. Eligible 
patients with and without pre-operative laboratory values were compared by ANOVA or chi-
square analysis to determine if their baseline characteristics differ significantly (p<0.05). Those 
with and without laboratory data by surgery type were evaluated to further understand any bias 
that may be introduced into the model. It may be the less invasive surgery types had fewer labs 
ordered by the surgeon due to the perception of lower risk of mortality. Any significant 
differences are noted in limitations. It is not possible to control for selection bias in this sample 
when we do not have physician- or hospital-level factors necessary to generate an appropriate 
selection model.   
Development of the Multivariable Mortality Model  
A Poisson model with binary in-hospital mortality as the outcome was used. This model 
is has two advantages over logistic regression [48, 49]. First, it computes incident risk ratios 
(IRR) as relative risks, which facilitates interpretation[49, 50]. Second, when cross-sectional data 
have frequent outcomes of interest, odds ratios (OR) may overestimate the prevalence in the 
sample[50]. Poisson is appropriate for a binary outcome model when relative risk is desired and 
events of interest are frequent. The Poisson model requires Huber-White standard error 
adjustment (robust standard errors) to avoid under-dispersion[49, 50]. If a variable was not 
significant, I tested for joint significance (p<0.05). If there was joint significance with other 
variables in the model, I included these measures in the final model for validation.  
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Validation of the Mortality Model 
After determining the predictors of mortality using a Poisson model, a logistic regression 
maximum likelihood model with a binary outcome (mortality) was used to obtain in-range 
predictions. Predictions for Poisson models (used for development) are often not appropriate for 
validation methods discussed earlier and shown in Table 1 [51]. I will report ORs for the 
mortality estimates. Predictions from the model will be compared to those that actually died in-
hospital after the index surgery. I am interested in the predictions from the model and how they 
compare to the actual outcome. I will obtain the predicted probability of death for each patient in 
the sample. The actual outcome is binary with 1 equal to death. Having a binary outcome makes 
it difficult to compare predictions that are continuous between 0 and 1. It will be necessary to 
perform a cut-point (i.e., threshold) analysis to determine where along the range of predicted 
probabilities the sensitivity and specificity are optimized (e.g., where do you call a “positive” 
result=death versus a negative result=survive)[52, 53]. 
Assessment of Mortality Model Performance 
Overall model performance will be assessed with the Brier score [52, 53] (Table 3). Brier 
scores measure the distance between the actual outcome and the predicted outcome[53]. Brier 
scores are similar to the Pearson’s R2 statistic. It is a quadratic scoring equation that uses the 
squared differences between the actual binary outcome (died/survive) and the predictions (p). 
[Brier score=(Y-p)
2
] [52]. The lower the Brier score, the better the predictions are calibrated to 
the actual outcome; for a perfect model with optimal fit, the Brier score equals zero. The Brier 
score is affected by the incidence of the outcome of interest in the population. When the 
incidence of the outcome is lower in the sample, the upper limit of the Brier score is lower.  
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I calculated the Brier score’s upper limit using incidence of mortality in the NSQIP 
sample. I have 30-day mortality incidence of 12.36%. This means our maximum Brier score 
would be: (Incidence-1)
2
, which gives an upper limit of 0.7680 for an uninformative model. For 
this study, I will calculate the Brier score for all patients in the sample and use the mean Brier 
score to assess the model’s accuracy. 
It is not necessary to know the point where we call the prediction positive or negative 
(cut-point) for computing the Brier score. We will need to know the cut-point when evaluating 
performance at different areas under the receiving operating characteristic (AUROC) curve 
discussed later. Calibration (model fit) of a predictive model refers to the process of creating the 
model and running it on a population that is not used to generate the predictions[53].  
 Cross-validation will be used to predict the performance of the model in an external 
dataset [52, 54] (Table 3). The algorithm can be assessed for its performance in an external 
dataset by folding the data repeatedly on a subset of the observations (multiple training sets) and 
applying it to the remaining observations multiple times (validation sets). K-fold cross-validation 
has been shown to be more efficient and a good substitute for training set and validation methods 
when sample size is limited [52, 54]. Cross-validation was chosen over creating a single training 
and validation set of patients due the rapidly changing surgical methods and procedures in our 
data. For example, if we reserve year 2011 for training and apply that to data from 2012–2013, 
the algorithm may fail due to newer procedures that reduce mortality or shifting populations 
(aging baby boomers in the cirrhotic cohort). Therefore, it is optimal to train the algorithm on 
multiple samples selected from different years then apply it to multiple validation samples from 
the same years (at least 10 k-folds). 
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The ability of the model to discriminate between those who survived or not will be 
evaluated using AUROC curves [52] (Table 3). Calibration will be assessed by the calibration-
in-the-large and calibration-in-the-small measures. Both measures are decomposed from the 
Brier score. Calibration-in-the-large measures the discrepancy between the mean predicted 
probability and observed fraction of positive outcomes. Taking the square root of this value gives 
you the percentage difference between the prediction and the actual positive outcome. 
Calibration-in-the-small measures the difference between the predictive probability and actual 
outcome within the groups[52]. 
To determine the cut-point for the predicted probability of death that best agrees with the 
actual outcome, decision curve analysis will be performed[53] (Table 3). This analysis compares 
the net number of true positives gained by using the model plotted against a range of thresholds 
(probability of death cut-points). The cut-point that results in the greatest number of true 
positives will be chosen for the model. 
Comparison of the Mortality Model to the MELD Score 
For this analysis, we will use only patients that have laboratory values to generate both 
the MELD score and the mortality model. Those with and without laboratory values will be 
compared. If significant differences are observed, they will be listed as a limitation and 
addressed in future validation efforts. 
I will use a chi-square statistic distributed with one degree of freedom to compare the 
AUROC for each model to the MELD score [53]. The MELD score will be calculated for each 
patient in the cohort using the Mayo Clinic MELD score algorithm: 
MELD Score = (0.957 * ln(serum creatinine) + 0.378 * ln(serum bilirubin) + 1.120 * 
ln(PT INR) + 0.643 ) * 10 (if hemodialysis, value for creatinine is automatically set to 4.0) 
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The AUROC for the MELD score will be calculated and compared to the new predictive 
model [22, 53]. I expect the mortality model to have a greater AUROC than the MELD score 
when predicting post-surgical in-hospital mortality. I expect this difference to be significant with 
p<0.05. 
Sample Size and Power Determination 
 To estimate sample size and power, I use methods that are appropriate for diagnostic 
tests[55] (Table 4). A predictive model is similar to a diagnostic where sensitivity and specificity 
of the predictions determine the usefulness of the model. We want to optimize true positive and 
true negative predictions while minimizing false positives and false negatives. Jones et al. 
propose two separate calculations to determine sample size, one for optimizing sensitivity and 
one for optimizing specificity[55]. It is desirable to have the sample size to meet both 
requirements. We estimate power and sample size based on the assumption that our predictive 
models will not be less than 80% sensitive or 80% specific when compared to actual outcomes 
(mortality and readmission). The incidence of mortality was calculated. Overall 608/4,916 
patients died regardless of death in or out of the hospital (12.36%).  
Power Calculation Using a Sensitivity Threshold (Table 4) [55] 
 
1
st 
calculation: TP+FN=z
2
 * (SN (1-SN)/w
2
  
 
Using the 1
st
 calculation, we determine sample size based on the lowest possible 
acceptable sensitivity—here we use 80%. z2 is set equal to 1.96 for a 95% confidence interval. 
We set alpha to 0.05 (5% threshold on each side of our sensitivity is allowable). 
Where: 
TP=true positives 
FN=false negatives 
Z=1.96 (95% confidence interval (CI)) 
SN=sensitivity 
W=accuracy threshold (alpha) of 0.05 
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P=population mortality incidence (12.36%) 
 
Then 1.96
2
 *(0.80(1-0.80))/0.05
2
=246 (sample size without taking into account the 
population incidence). 
 
2
nd 
calculation
 
: N(sN)=TP + FN/P 
Using n=246 obtained in the first calculation and an incidence of 16.06% for deaths for 
cirrhotic patients obtained from our NSQIP data, we obtain: N(sN)=246/0.1236= 1,990 patients. 
The sample size is sufficient to power the study. 
 
Power Calculation Using a Specificity Threshold [55] 
1
st 
calculation: FP+TN=z
2
 * (SP (1-SP)/w
2
  
 
Using the 1
st
 calculation, we determine sample size based on the lowest possible 
acceptable specificity—here we use 80%. z2 is set equal to 1.96 for a 95% confidence interval. 
We set alpha to 0.05 (5% threshold on each side of our specificity is allowable). 
 
2
nd 
calculation: N(sN)=FP + TN/(1-P) 
 
Where: 
TP=true positives 
FN=false negatives 
Z=1.96 (95% CI) 
sN=sensitivity 
W=accuracy threshold (alpha) of 0.05 
P=population incidence (12.36%) 
 
Then 1.96
2
*(0.80(1-0.80))/0.05
2
=246 (sample size based on specificity not accounting for 
mortality incidence in the sample). 
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Using 246 obtained from the first calculation and using an incidence of 12.36% for 
deaths in cirrhotic patients obtained from the NSQIP data. We obtain: N(sN)=246/(1-
0.1236)=280 patients. Our sample size is sufficient to power the study. (Table 4) 
Results 
Bivariate Analyses (Table 5) 
The mortality cohort included 4,916 patients, 608 patients of whom died prior to 
discharge and 4,308 of whom were discharged alive. In the unadjusted analyses, 15.1% of 
patients were between 71 and 80 years of age and had a significantly greater incidence of 
mortality compared to those discharged alive in this age category (19.1%; p=0.004). Patients 
aged 41–50 had significantly better lower post-surgical mortality (10.2%; p=0.02).  
 Patients with normal renal function (eGFR>90) had significantly lower mortality. Any 
degree of kidney dysfunction was associated with significantly greater mortality rates.  
 43.5% of cases were an emergent surgical procedure. Mortality was significantly greater 
than those surviving emergency surgical procedures (70.6% versus 39.3%; p<0.001). 
  Patients having a pre-operative comorbidity of confusion, alcohol use, chronic 
obstructive pulmonary disease, or chronic heart failure had greater incidence of in-hospital 
mortality. Underweight patients had a greater mortality incidence (7.1% versus 4.6%; p=0.01).  
 Functional status, ASA classification, MELD score, Childs-Pugh category, AST to 
platelet (APRI) score, and total length of stay were all associated with post-surgical mortality in 
the unadjusted analyses. All pre-operative laboratory values were significantly associated with 
mortality except for serum sodium. The total length of the hospital stay was associated with 
mortality with a mean stay of 14 days for those who died versus 9 days for those discharged 
(p<0.001). 
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Comparison of Cirrhotic Cohort with and without Laboratory Values (Table 6) 
 To assess missing pre-operative laboratory values, I compared patients with and without 
values in an unadjusted analysis. Patients either had all laboratory values necessary to generate 
the MELD score, mortality model, and readmission model or were missing values that would 
prohibit generation of any of the three models. Significant differences (p<0.05) indicates data 
may not be missing at random. 
 In the unadjusted analyses, white patients were more likely to have pre-operative 
laboratory values (p=0.03) while other races (non-white and non-black) were less likely to have 
pre-operative labs (p<0.001). Patients having an emergent procedure were less likely to have pre-
operative labs (p<0.001).  
 Patients having a less invasive laparoscopic procedure were less likely to have pre-
operative lab values available (p<0.001). Hernia repair patients were more likely to have labs 
(p=0.005). If functional status was totally dependent, fewer patients had pre-operative labs 
(p<0.001). Patients with ASA classification of mild disturbance (p=0.02) and severe disturbance 
(p<0.001) were more likely to have lab values while those with life threatening (p=0.01) or 
moribund (p<0.001) status were less likely. 
 These laboratory data were not missing completely at random or missing at random. 
Therefore, the external validity of the analyses may be compromised given the selection bias 
present in the NSQIP. 
In-Hospital Mortality Model (Table 7) 
 The Poisson mortality model elucidated variables associated with mortality. As expected, 
advancing age is predictive of in-hospital mortality holding other variables constant. Patients 
between ages 51 and 60 had a 48.5% risk (IRR 1.485; p=0.047) of post-surgical death prior to 
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discharge compared to those <40 years (referent). As age increased, the risk increased to two 
times that of patients under 40 for the 71–80-year-olds (IRR 2.186; p<0.001) to >80 years (IRR 
2.382; p<0.001).  
 In general, patients with poorer clinical/health status at baseline were at increased risk of 
death. Compared to patients that were fully independent, having a functional status of partially 
dependent carried a 36.5% (p=0.009) relative risk of death while those totally dependent had a 
relative risk of 38.4% (p=0.002) holding all other variables constant. Those with an ASA 
classification of life-threatening (IRR 4.030; p<0.001) or moribund (IRR 5.478; p<0.001) had a 
significantly greater risk of death compared to patients with mild disturbance (referent). The pre-
operative eGFR, albumin, platelet count, total bilirubin, and prothrombin INR laboratory values 
were all predictive of post-surgical mortality. Patients having emergency surgery had a 69.8% 
(p<0.001) greater risk of death compared to scheduled surgery. Hernia repair surgery, whether 
laparoscopic or open, carried a 45.8% (p=0.025) reduction in the risk of death compared to other 
non-hernia open abdominal procedures. No other surgical category showed significant 
differences in risk compared to open abdominal surgeries. 
Final Mortality Model (Table 8) 
Mortality model: In-hospital mortality= β0 + β1 Age + β2 Gender + β3 BMI + β4 Functional 
Status + β5 ASA classification + β6 Race + β7 Race + β8 eGFR + β9 Albumin + β10 Platelet 
count + β11 WBC + β12 Total bilirubin + β13 PT INR + β14 Sodium + β15 Emergency 
surgery + β16 Type of surgery + β17 Comorbidities + β18 Surgery category 
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 All variables chosen a priori were kept in the model based on literature support. BMI was 
the only variable dropped from the model. BMI may be inaccurate because weight may reflect 
ascites rather than obesity in patients with decompensated cirrhosis.  
 Although hernia repair was the only surgery type to show a protective effect against 
mortality when compared to non-hernia open abdominal procedures, other surgery types were 
left in the model to control for complexity of the procedure and risk attributable to a specific 
procedure type. For example, cardiothoracic surgery may carry greater risk of mortality than a 
laparoscopic procedure. Diabetes, chronic heart failure, and COPD were not significant in the 
Poisson model but included in the final model to control for comorbidities known to carry risk of 
mortality.  
 The final mortality model employed a logistic regression reporting ORs. Predictions were 
obtained for the model and interpreted as the probability of death prior to discharge after the 
index surgery. The final model included 1,945 patients (Table 8). Advancing age was predictive 
of mortality with odds increasing from 2.041 (p=0.029) in the 51–60 group to 4.385 (p<0.001) in 
patients >80 years of age compared to the <40 referent group, holding other factors constant. 
Functional status, albumin, platelet count, total bilirubin, prothrombin INR, emergent surgery, 
and hernia repair were all significant predictors of mortality (p<0.05). 
Validation of the Mortality Model (Table 9) 
 To assess calibration, calibration-in-the-large, calibration-in-the-small, and Hosmer-
Lemeshow goodness-of fit tests are reported. Calibration-in-the large is a property of the entire 
mortality cohort sample. The mortality model had a calibration-in-the-large value of 0.0004. By 
taking the square root of this value, the model shows a 2% difference between the mean 
predicted probability of death and the actual mean of the binary outcome. Calibration-in-the-
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small measures the error within the groups (died vs. discharged alive). The mortality model had a 
value of 0.0014 that translates to 3.7% difference in the predicted probabilities versus the actual 
outcome within groups. Finally the Hosmer-Lemeshow goodness-of-fit test indicates if the 
model is correctly specified. In this case, the p-value for this test was 0.345. This is not 
significant at a threshold of p<0.05 indicating the model is correctly specified. 
 Discrimination was assessed using AUROC curves, sensitivity, specificity, positive 
predictive value, negative predictive value, and percent correctly classified at a chosen cut-point. 
The cut-point that maximized the sensitivity of the model and kept specificity above 60% was 
0.2150 (also see the decision curve analysis). This model achieved an AUROC of 0.8282. The 
sensitivity was 81.1%, specificity 73.6%, positive predictive value 47.6%, and negative 
predictive value 92.9%. We achieved our goal of at least 0.80 for the AUROC. The sensitivity 
exceeded our goal of at least 80% but the specificity of the model did not reach the goal of 80%.  
 We used the k-fold (k=10) and leave-one-out methods to cross-validate the model. Both 
the k-fold and leave-one-out methods exceeded our AUROC threshold of 0.80 (k-fold: 0.8402; 
leave-one-out: 0.8420). The Brier score, which considers both the calibration and discriminatory 
ability of the model, was 0.1269, which is well below the threshold for a non-informative model.  
Decision Curve Analyses (Figure 3) 
 The decision curve analysis indicates predicted probabilities where the model is useful as 
a decision tool versus using no tool (greatest net benefit). Figure 3 indicates the model may 
reduce post-surgical deaths (net benefit) if used between 10% and 75% predicted probability of 
mortality. Above 75%, predictions about whether a patient should have surgery are not useful 
given the high probability of post-surgical mortality without using the model. For probabilities 
below 10% the model is not useful given the low probability of death. Below 10% and above 
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75%, the model contributes no information beyond the surgeon’s assessment of risk. The point 
on the decision curve that maximizes the net benefit of the model to identity true positives is 
0.2150 and is where the maximum net benefit is gained. 
Comparison of the Model to the MELD Score (Figure 5) 
 The AUROC curve for the mortality model (0.8422) was significantly (p<0.001) better 
than the MELD (0.7405). Across the range of cut-points, the mortality model is better at 
predicting post-surgical deaths than the MELD score. This means the NSQIP mortality model is 
better at discriminating between those who died and those who were discharged alive versus the 
MELD score. If using the NSQIP mortality model, a clinician would be better able to classify 
patients by their risk of death post-operatively. 
Discussion 
 The decision to take a patient with decompensated cirrhosis to surgery is difficult for 
surgeons, given the patient’s risk of death. Currently, surgeons often look to the MELD score, 
even though it was not developed to predict death. We developed and validated the NSQIP 
Mortality Model, which is significantly better (p<0.001) than the MELD score when predicting 
post-surgical in-hospital mortality in patients with decompensated cirrhosis. This is, perhaps, not 
surprising because the variables we included were clinically sensible—for example, age, pre-
operative laboratory values, etc. 
 We found that surgery type carries different levels of risk. For example, cardiothoracic 
surgery carries more risk than a laparoscopic hernia repair. Therefore we kept surgery type in the 
model to control for varying levels of risk. Not surprisingly, hernia repair was performed most 
often by a laparoscopic procedure and offered a protective effect. Although any non-hernia/non-
cholecystectomy laparoscopic procedure was not significant in the model, the estimate does not 
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show a protective effect for the less invasive surgery. This may be due to selection bias in the 
sample. Sicker patients are selected for the less invasive laparoscopic procedures and thus carry a 
greater risk of mortality. 
 In terms of pre-operative laboratory values, albumin was strongly associated with 
mortality. Cirrhotic patients tend to struggle with decreasing albumin levels. The model showed 
that for every one point increase in albumin prior to surgery, the risk of mortality was reduced by 
35% on average. This may suggest that getting patient’s albumin levels up prior to surgery could 
be beneficial in reducing risk of mortality. Increases in total bilirubin and the PT INR were also 
strongly associated with mortality. For each point increase in bilirubin prior to surgery, the 
model showed a 22.9% increase in risk of death. For each point increase in PT INR, there was an 
87.3% increase in the risk of post-surgical mortality. It is well known that liver dysfunction 
contributes to increased bilirubin and prothrombin, and our data suggest that close attention 
should be paid to these pre-operative laboratory values prior to taking patients to surgery.  
 The model performed significantly better than the MELD score. In the decision curve 
analysis (Figure 3), the AUROC curve for the NSQIP Mortality Model is greater than for the 
MELD score. This difference represents the net benefit of using the NSIP Mortality Model to 
decide to take a patient to surgery across a range of predicted probabilities. Moreover, the 
NSQIP Mortality Model showed net benefit between across a broader range of predicted 
probabilities (10%–76%) than the MELD Score (22%–39%). Having a model that can predict 
mortality risk across the middle-range of threshold probabilities is of greater value to the 
surgeon. It is in this middle range of risk that decisions to proceed to surgery become difficult 
and the model offers the most net benefit. 
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This study has several limitations. First, there is selection bias. Given that pre-operative 
serum sodium was not predictive of mortality supports selection of healthier patients for surgery. 
In patients with liver cirrhosis, sodium has been found to be associated with mortality in multiple 
studies[56, 57]. Surgeons often avoid surgery on patients who have a low or elevated sodium 
value due to its association with mortality. They assume these patients are at great risk of death 
post-operatively and choose not to proceed. These patients will not be included in the NSQIP 
database.  
Second, laboratory values were not missing completely at random, which may have 
introduced bias into our models. One concern is that patients undergoing a laparoscopic 
procedure had fewer laboratory values necessary to generate the models and the MELD score 
than those undergoing more invasive (non-lap) procedures. Patients undergoing hernia repair had 
laboratory values available more often than those having non-hernia repair procedures. Further 
research in external samples is required to address the potential bias introduced by missing 
values. Imputation or selection models could have been undertaken but given the wide variation 
in laboratory values in decompensated cirrhotic patients, they were not chosen as options due to 
the fear of introducing more bias.  
 On the one hand, the estimates we obtain may be biased by the inability to control for the 
two types of selection bias present in the data[58]. On the other hand, the NSQIP is designed 
specifically to capture pre- and post-surgical risk or mortality and readmission[44]. There is no 
better database to stratify patients undergoing surgery by risk of mortality and readmission. It is 
possible to evaluate risk factors prior to, during and after surgery.  
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Next Steps 
 The mortality model performed well in this sample. However, more validation is 
necessary prior to using the model to make informed decisions regarding surgery. Once 
validation is completed in a prospective, real-world study, a risk score can be provided through 
the EMR. This score may appear as: “72% risk of mortality predicted: In studies of patients with 
decompensated liver cirrhosis and predicted probability of mortality of >60%, surgery is not 
recommended for X-type surgery.” This will inform decisions made between the hepatologist, 
surgeon, and patient.  
 Future studies will evaluate the mortality model in a real-world setting. I intend to 
implement the model in an electronic medical record (EMR) system for external validation. 
Because data in the model are collected in real time, the predicted probabilities can be classified 
based on patients’ outcomes. For example, if the model is allowed to run in an EMR for one year 
across several hospitals, enough data could be collected to group the predictions into clear go or 
no-go categories. A clear cut-point may emerge to inform the surgical decision. If a single cut-
point does not emerge, risk categories (Low/Medium/High) may be established to help the 
surgeon and patient decide if surgery is advisable. Validation of predictive models is a long and 
dynamic process. Until it is clearly proven the model works in multiple settings and across 
different surgery types, it cannot be implemented into practice. 
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CHAPTER 4. THE NSQIP READMISSION MODEL 
Introduction 
Decompensation increases the risk of unplanned readmissions [10-12]. Compared to 
patients without cirrhosis, those with cirrhosis had among the highest odds of unplanned 
readmissions[4, 11, 12, 59]. Patients with cirrhosis who undergo surgery are frequently 
readmitted within 30 days[12]. This is concerning for both the patients and the healthcare 
system. The ability to predict the risk of 30-day readmission would potentially reduce unplanned 
readmissions by allocating resources for support patients at the greatest risk of readmission[18]. 
The urgency to predict readmissions is fueled by financial penalties imposed on hospitals by the 
Centers for Medicare and Medicaid Services (CMS) for Medicare patients with 30-day 
readmissions [16, 17]. As the cirrhotic population ages, more will have Medicare as their 
primary payer and expose hospitals to the risk for significant financial penalties [17]. Other 
payers will likely adopt CMS’s reimbursement strategies for 30-day readmissions. As CMS 
begins its bundled payments for the care improvement initiative, it will be critical to a hospital’s 
financial health to know the risk of a prolonged stay or complication prior to the service provided 
(e.g., surgical procedure).   
 Currently, no validated model exists to predict readmission among patients with cirrhosis 
who undergo surgery. This study aimed to develop and validate a readmission predictive model 
and then compare its ability to predict readmission to the MELD score in patients undergoing 
surgery. 
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Methods 
Data Source and Sample Selection 
This study used the American College of Surgeons National Quality Improvement 
Program data from 2011–2013[44]. NSQIP is a national voluntary program to help hospitals 
reduce surgical morbidity and mortality. The program offers three levels of participation that 
vary by labor intensity to allow smaller hospitals with limited resources to participate. To date, 
more than 300 hospitals nationwide participate in the NSQIP[44]. 
Data are collected through a combination of electronic medical records and manual chart 
abstraction at each site. More than 150 variables are collected on surgical cases. Each year, 
hospitals rotate through 46 eight-day cycles of data collection to capture a random sampling of 
surgical cases. Included are patients having a major surgery (defined by CPT code) during one of 
the eight-day collection cycles. Both emergent and non-emergent surgeries are captured. Trauma 
and transplant surgeries are excluded[44, 45].  
Data are collected at the patient level. Pre-, intra-, and post-operative variables are 
collected for each patient. If a patient died prior to discharge, he or she is captured in the 
discharge status variable with an “expired” status[44]. Up to five unplanned readmissions are 
captured within 30 days from the index surgery in readmission outcome variable[44].  
Identifying Patients with Liver Cirrhosis 
I selected patients with liver disease, defined as having an esophageal hemorrhage or 
ascites as defined by the ACS NSQIP[44]. The ACS NSQIP definition for these variables 
requires a history of liver disease on record concurrent with an esophageal varices or ascites 
diagnosis[44, 45]. For these patients, I will use previously validated laboratory values that define 
liver cirrhosis: platelet value of < 140,000/mm
3 
and albumin <3.5 g/dL and prothrombin 
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INR>1.5 [45-47]. Finally, any patient with disseminated cancer, an outpatient surgery, or a do 
not resuscitate (DNR) order on file, as defined by a variable in the NSQIP, was removed. This 
resulted in a final cohort of patients with liver cirrhosis (n=4,916).  
Readmission Model Cohort  
Aims 1b, 2b, and 3b will be restricted to the 4,308 patients who were discharged alive 
after the index surgery (Figure 2). Of those, I determined who was readmitted versus those that 
were not readmitted within 30 days from the index surgery. The predictive model will be used 
for patients that are at risk of having an unplanned readmission within 30 days after the index 
surgery and subsequent discharge. Our final cohort for analysis in aims 1b, 2b and 3b will 
include patients with laboratory values to generate the MELD score and readmission model 
(readmitted: n=542) and (n=2,970 discharged alive but not readmitted within 30 days). 153 
patients were excluded due to missing laboratory values. 
Bivariate Analyses 
 Patients with and without a readmission were compared using ANOVA, chi-square, and 
non-parametric test for trends in ordered variables (Table 5). Eligible patients with and without 
pre-operative laboratory values were compared by ANOVA or chi-square analysis to determine 
if their baseline characteristics differ significantly (p<0.05) (Table 6). Those with and without 
labs by surgery type were evaluated to further understand any bias that may be introduced into 
the model. It may be the less invasive surgery types had fewer labs ordered by the surgeon due to 
the perception of lower risk of mortality. Any significant differences are noted in limitations. It is 
not possible to control for selection bias in this sample when we do not have physician- or 
hospital-level factors necessary to generate an appropriate selection model.  
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Development of the Multivariable Readmission Model 
We used a Poisson model with a binary outcome (readmission within 30 days of 
discharge from the index surgery) to determine predictors of readmission [48, 49]. This model is 
has two advantages over logistic regression [48, 49]. First, it computes incident risk ratios (IRR) 
as relative risks, which facilitates interpretation[49, 50]. Second, when cross-sectional data have 
frequent outcomes of interest, odds ratios (OR) may overestimate the prevalence in the 
sample[50]. Poisson is appropriate for a binary outcome model when relative risk is desired and 
events of interest are frequent. The Poisson model requires Huber-White standard error 
adjustment (robust standard errors) to avoid under dispersion[49, 50]. If a variable was not 
significant, I tested for joint significance (p<0.05). If there was joint significance with other 
variables in the model, I included these measures in the final model for validation. Ultimately, 
literature support guided final selection of variables in the model regardless of significance. 
Validation of the Readmission Model 
After determining the predictors of readmission using a Poisson model, a logistic 
regression maximum likelihood model with a binary outcome was used to obtain in-range 
predictions. Predictions for Poisson models (used for development) are often not appropriate for 
validation methods discussed earlier and shown in Table 1 [51]. I will report ORs for the 
readmission estimates. Predictions from the model will be compared to those that were 
readmitted after the index surgery. I am interested in the predictions from the model and how 
they compare to the actual outcome. I will obtain the predicted probability of readmission for 
each patient in the sample. The actual outcome is binary with 1 equal to death. Having a binary 
outcome makes it difficult to compare predictions that are continuous between 0 and 1. It will be 
necessary to perform a cut-point (i.e., threshold) analysis to determine where along the range of 
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predicted probabilities the sensitivity and specificity are optimized (e.g., where do you call a 
“positive” result=readmission versus a negative result=no readmission)[52, 53]. 
Assessment of the Readmission Model Performance 
Overall model performance will be assessed with the Brier score [52, 53] (Table 3). Brier 
scores measure the distance between the actual outcome and the predicted outcome[53]. Brier 
scores are similar to the Pearson’s R2 statistic. It is a quadratic scoring equation that uses the 
squared differences between the actual binary outcome (died/survive) and the predictions (p). 
[Brier score=(Y-p)
2
] [52] The lower the Brier score, the better the predictions are calibrated to 
the actual outcome; for a perfect model with optimal fit, the Brier score equals zero. The Brier 
score is affected by the incidence of the outcome of interest in the population. When the 
incidence of the outcome is lower in the sample, the upper limit of the Brier score is lower.  
It is not necessary to know the point where we call the prediction positive or negative 
(cut-point) for computing the Brier score. We will need to know the cut-point when evaluating 
performance at different areas under the receiving operating characteristic (AUROC) curve 
discussed later. Calibration (model fit) of a predictive model refers to the process of creating the 
model and running it on a population that is not used to generate the predictions[53].  
 Cross-validation was used to predict the performance of the model in an external dataset 
[52, 54] (Table 3). The algorithm can be assessed for its performance in an external dataset by 
folding the data repeatedly on a subset of the observations (multiple training sets) and applying it 
to the remaining observations multiple times (validation sets). K-fold cross-validation has been 
shown to be more efficient and a good substitute for training set and validation methods when 
sample size is limited [52, 54]. Cross-validation was chosen over creating a single training and 
validation set of patients due the rapidly changing surgical methods and procedures in our data. 
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For example, if we reserve year 2011 for training and apply that to data from 2012–2013, the 
algorithm may fail due to newer procedures that reduce mortality or shifting populations (aging 
baby boomers in the cirrhotic cohort). Therefore, it is optimal to train the algorithm on multiple 
samples selected from different years then apply it to multiple validation samples from the same 
years (at least 10 k-folds). 
The ability of the model to discriminate between those who were readmitted or not will 
be evaluated using AUROC curves [52] (Table 3). Calibration will be assessed by the 
calibration-in-the large and calibration-in-the small measures. Both measures are decomposed 
from the Brier score. Calibration-in-the-large measures the discrepancy between the mean 
predicted probability and observed fraction of positive outcomes. Taking the square root of this 
value gives you the percentage difference between the prediction and the actual positive 
outcome. Calibration-in-the-small measures the difference between the predictive probability and 
actual outcome within the groups[52]. 
To determine the cut-point for the predicted probability of readmission that best agrees 
with the actual outcome, decision curve analysis will be performed[53] (Table 3). This analysis 
compares the net number of true positives gained by using the model plotted against a range of 
thresholds (probability of death cut-points). The cut-point that results in the greatest number of 
true positives will be chosen for the model. 
Comparison of the Readmission Model to the MELD Score 
For this analysis, we will use only patients that have laboratory values to generate both 
the MELD score and the readmission model. Those with and without laboratory values will be 
compared. If significant differences are observed, they will be listed as a limitation and 
addressed in future validation efforts. 
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I will use a chi-square statistic distributed with one degree of freedom to compare the 
AUROC for the model to the MELD score [53]. The MELD score will be calculated for each 
patient in the cohort using the Mayo Clinic MELD score algorithm: 
MELD Score = (0.957 * ln(serum creatinine) + 0.378 * ln(serum bilirubin) + 1.120 * 
ln(PT INR) + 0.643 ) * 10 (if hemodialysis, value for creatinine is automatically set to 4.0) 
 
 The AUROC for the MELD score will be calculated and compared to the new predictive 
model [22, 53]. I expect the mortality model to have a greater AUROC than the MELD score 
when predicting post-surgical in-hospital mortality. I expect this difference to be significant with 
p<0.05. 
Sample Size and Power Calculation 
To estimate sample size and power, I use methods that are appropriate for diagnostic 
tests[55] (Table 4). A predictive model is similar to a diagnostic where sensitivity and specificity 
of the predictions determine the usefulness of the model. We want to optimize true positive and 
true negative predictions while minimizing false positives and false negatives. Jones et al. 
propose two separate calculations to determine sample size, one for optimizing sensitivity and 
one for optimizing specificity. It is desirable to have the sample size to meet both requirements. 
We estimate power and sample size based on the assumption that our predictive models will not 
be less than 80% sensitive or 80% specific when compared to actual outcomes (mortality and 
readmission). 
 Calculation of the incidence of readmission within 30 days: Overall 566/4,308 (13.14%) 
had any unplanned readmission. Using Jones et al. equations with a lower limit for sensitivity 
and specificity of 80%, we can estimate the sample size for the readmission model. We found 
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readmissions in the cirrhotic cohort were 13.14%. Using the incidence of readmission we find 
the following: 
Sensitivity: N(sN)=246/0.1314=1,872 total patients in sample  
Specificity: N(sN)=246/(1-0.1314)=283 total patients 
The sample size is sufficient to power the study. (Table 4) 
Results 
Bivariate Analyses (Table 5) 
 Patients discharged with a 30-day readmission were compared to those without on 
multiple variables. I found advanced age was not associated with readmission in patients with 
decompensated cirrhosis. Insulin-dependent diabetes was associated with readmission in 
(p=0.001). Patients classified into the ASA class moribund or life-threatening had significantly 
more readmissions. 
 The pre-operative laboratory values for albumin, sodium, total bilirubin, platelets, PT 
INR, and white blood cell count showed significant differences between those with an unplanned 
readmission versus those without. Patients with a MELD score of less than or equal to 9 (less 
severe disease) had significantly more readmissions (p=0.002). Those with MELD scores 
between 10 and 19 also had significantly fewer readmissions (p=<0.001).  
Comparison of Cirrhotic Cohort with and without Laboratory Values (Table 6) 
 To assess missing pre-operative laboratory values, I compared patients with and without 
values in an unadjusted analysis. Patients either had all laboratory values necessary to generate 
the MELD score, mortality model, and readmission model or were missing values that would 
prohibit generation of any of the three models. Significant differences (p<0.05) indicates data 
may not be missing at random. 
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 In the unadjusted analyses, white patients were more likely to have pre-operative 
laboratory values (p=0.03) while other races (non-white and non-black) were less likely to have 
pre-operative labs (p<0.001). Patients having an emergent procedure were less likely to have pre-
operative labs (p<0.001).  
 Patients having a less invasive laparoscopic procedure were less likely to have pre-
operative lab values available (p<0.001). Hernia repair patients were more likely to have labs 
(p=0.005). If functional status was totally dependent, fewer patients had pre-operative labs 
(p<0.001). Patients with ASA classification of mild disturbance (p=0.02) and severe disturbance 
(p<0.001) were more likely to have lab values while those with life-threatening (p=0.01) or 
moribund (p<0.001) status were less likely. 
 These laboratory data were not missing completely at random or missing at random. 
Therefore, the external validity of the analyses may be compromised given the selection bias 
present in the NSQIP. 
NSQIP Unplanned 30-Day Readmission Model (Table 10)  
 Age, gender, body mass index, functional status, race, surgery type, discharge 
destination, and emergent surgery were not significant predictors of readmission in the model. 
However, using a p-value significance threshold of less than 0.05, gender and discharge to a 
rehabilitation facility were borderline significant with p-values of 0.05. 
 Having an ASA classification of life-threatening increased the risk of readmission by 
62.8% (p=0.009) compared to those classified as having a mild disturbance while holding other 
variables constant. For every 1 point increase in albumin, there is a 14.7% (p=0.049) reduction in 
the risk of readmission. For every increase in the PT INR, there is a 48.0% (p=0.003) increase in 
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the risk of readmission. Patients who are insulin dependent have a 61.7% (p=0.001) increase in 
the risk of being readmitted compared to non-diabetics. 
 Certain post-operative complications were found to increase the risk of readmission. 
Sepsis dramatically increased the risk of readmission by 96.6% (p<0.001). Acute or progressive 
renal failure increased readmission risk by 57.0% (p=0.032) while a urinary tract infection 
increased risk more than two-fold (RR 2.25; p=0.001). If a patient had an unplanned intubation, 
the risk of readmission increased by 51.8% (p=0.038). 
 Time on the operating table contributes to the risk of readmission. For every additional 
hour spent on the table, the risk of readmission was increased by 12.0% (p=0.002). 
Final NSQIP Readmission Model (Table 11) 
Readmission model: Readmission (within 30 days of index surgery)= β0 + β1 Age + β2 
Gender + β3 BMI + β4 Functional Status + β5 ASA classification + β6 Race + β7 Race + β8 
eGFR + β9 Albumin + β10 Platelet count + β11 WBC + β12 Total bilirubin + β13 PT INR + 
β14 Sodium + β15 Emergency surgery + β16 Type of surgery + β17 Comorbidities + β18 
Surgery category + β19 Discharge destination + β20 Pneumonia + β21 Sepsis + β22 Time on 
table + β23 Time under anesthesia + β24 Acute/Progressive Renal Failure + β25 Urinary Tract 
Infection + β26 Ventilator Wean Time >48 hours + β27 Total Length of hospital stay + 
constant 
 
 All variables, regardless of significance in the Poisson model were kept in the final logit 
readmission model. Readmissions are notoriously difficult to predict. The Poisson model was 
used to find significant predictors of readmission. However, when using only significant 
predictors in the logit model, important factors that need to be controlled for (in theory) are lost 
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and may cause bias in predictors left in the model (joint significance). It is best practice to keep 
all variables in the readmission model, regardless of significance, because theory and literature 
dictate they contribute to readmission risk. For example, age is not significant in the Poisson 
model or logit model but there is support in the literature that advancing age increases the risk of 
readmission [17]. Omission of important variables may lead to omitted variable bias. However, 
including too many variables may result in over-fitting of the model. Subsequent tests were 
conducted to guard against over-fitting (see validation section). The final decision was to keep 
all variables from the Poisson model in the final readmission model. This was driven by theory 
and literature support. 
 Being male was found to decrease the odds of readmission compared to females (OR 
0.705; p=0.041). Several laboratory values were predictive of readmission. As albumin increases 
by one point, the odds of readmission also decreased (OR 0.793; p=0.037). A one-point increase 
in PT INR increases the odds of readmission more than two-fold (OR 1.734; p=0.009). Patients 
who are insulin dependent have a two-fold increase in odds of readmission (OR 1.980; p=0.001).  
 Certain post-operative complications remained significant in the final model when 
predicting readmission. Post-operative sepsis increased the odds of readmission two-fold as did 
acute renal failure (OR 2.641; p<0.001 and OR 2.028; p=0.033). Urinary tract infection remained 
a strong predictor of readmission (OR 3.248; p=0.001). Patients that were discharged to a 
rehabilitation facility had lower odds of readmission compared to those discharged to a facility 
that was not home, acute care, or rehabilitation facilities (OR 0.452; p=0.041). 
Validation of the Readmission Model (Table 12) 
For the readmission model, calibration and discrimination were assessed. The calibration-
in-the-large was zero for this model. This indicates that for the entire readmission cohort, there is 
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no difference between the mean of all predictions and actual outcome. However, calibration-in-
the-small was 0.007 or 2.65% difference in the predicted mean of those readmitted versus the 
actual mean of those readmitted (within-group calibration). This is a well-calibrated model. The 
Hosmer-Lemeshow goodness-of-fit test was not significant (p=0.310), indicating the model is 
correctly specified.  
 The ability of the model to discriminate between those readmitted and those not 
readmitted was assessed. The AUROC was 0.7541 with a sensitivity of 76.6%, specificity of 
60.9%, positive predictive value of 27.7%, and negative predictive value of 93.0% at a cut-point 
of 0.1425. Neither the sensitivity nor specificity of the readmission model reached our goal of 
80%. 
 Although the model did not reach our 80% sensitivity and specificity goals, the out-of-
sample performance indicates a larger sample may improve performance. Cross-validation using 
the 10-fold method gave an AUROC of 0.7602. This is greater than the AUROC from running 
the full model and an indicator that performance in another sample or larger sample could 
improve performance. The leave-one-out method had an AUROC equal to that of the full model. 
 The Brier score was 0.1186. The maximum Brier score, accounting for 13.1% incidence 
of readmission, was 0.7540 for a non-informative model. Our Brier score was quite low, 
indicating good discrimination and calibration. Overall the model was able to classify 63.5% of 
the observations correctly. 
Decision Curve Analysis (Figure 4) 
The decision curve analysis showed the readmission model had a positive net benefit 
between threshold probabilities of 19% and 70%. This means that for those at very low risk of 
readmission (<19%) or those at very high risk (>70%) using the model to prevent readmissions is 
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of no benefit. A model that can inform decisions in the middle range for risk of readmission is 
most useful because this will be where it is difficult for a hospital to decide how to tier discharge 
planning to prevent readmission. 
 The point on the decision curve that maximizes true positives for readmission is 0.1425. 
This is where the maximum net benefit is gained by using the model. 
Comparison of the Readmission Model to the MELD Score (Figure 6) 
The readmission model was compared to the MELD score. Although the MELD score is 
not an optimal comparator and is not intended to predict readmissions, no other readmission 
model exists specifically for decompensated patients with cirrhosis undergoing surgery. The 
readmission model AUROC (0.7541) exceeded the MELD score AUROC (0.5663) when 
predicting 30-day readmission (p<0.001). 
Discussion 
Readmissions have been notoriously difficult to predict [60]. The combination of in-
hospital factors and patient-level factors after discharge are required to capture accurate risk of 
readmission. In our dataset, we had in-hospital factors. It is evident in the final readmission 
model there are few predictors that are significant. Prediction of in-hospital mortality relies on 
pre-, intra-, and post-operative factors that are captured in our dataset. When a patient is 
discharged the ability to capture important factors such as medication compliance and wound 
care is lost. Therefore, many readmission models, including this model, suffer from omitted 
variable bias. However, this model is a good start to finding predictors of readmission in 
decompensated cirrhotic patients. Further research will target data sources that capture out-of-
hospital factors. 
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 The current model had some surprising results. First, being male had a protective effect 
on readmission compared to females. There was a 29% decrease in the risk of readmission if 
male holding other factors constant (Table 10). This may be an artifact given over 50% of the 
patients in our sample are male (56.8%) or it could be that women are traditionally caretakers 
and have fewer resources for taking care of themselves. When they return home from the 
hospital, they may have less time to recover and address their own medical needs or may not 
have the support of a caretaker. Future studies would be warranted to investigate this hypothesis 
by capturing information on the home environment after discharge. 
 It was not surprising that having a life-threatening ASA classification was associated with 
readmission compared to those with mild disturbance. These patients are sicker and have greater 
baseline risk of complications after surgery. Patients with a moribund ASA classification were 
not associated with readmission. This may be due to the fact they are more likely to die after 
surgery given their grave health state.  
 The type of surgery, emergent surgery, and length of hospital stay were not predictive of 
readmission. This is surprising given that different surgery types carry variable levels of risk. It 
seems readmission may be more likely if undergoing a cardiothorasic procedure versus a hernia 
repair. Length of hospital stay has been associated with readmission in previous studies but our 
model did not show a significant association. It could be patients are hospitalized long enough to 
stabilize their health prior to discharge thus reducing the risk of readmission. In fact, discharge to 
a rehabilitation facility was associated with a 54.8% reduction in the risk of readmission 
compared to discharge to another type of facility that was not home or acute care (Table 10). 
Stabilizing patients with decompensated cirrhosis may be key to mitigating readmission. This 
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may include fluid management to prevent encephalopathy, protein management to stabilize 
albumin levels, and control of bleeding to avoid variceal hemorrhage.  
 Patients with insulin-dependent diabetes are almost two times as likely to be readmitted 
compared to those without diabetes. It is well established that liver dysfunction can make 
diabetes management difficult due to glycogen storage in the liver being impaired[61]. 
Readmission may be due to complications of slow wound healing or infection given both are 
frequent complications in diabetics.  
 There were no surprises in the post-operative predictors of readmission. Patients are at 
greater risk of infections even without surgery. Post-surgical urinary tract infections (UTI) 
increased the risk of readmission three-fold compared to those without a UTI. Sepsis increased 
readmission risk almost three-fold. Acute renal failure or progressive renal failure after surgery 
increased risk two-fold. Both sepsis and acute renal failure are common in decompensated 
cirrhotic patients even without surgery. Unplanned intubation after surgery was associated with 
readmission and may be a proxy for capturing post-surgical complications not available in the 
NSQIP database such as metabolic acidosis, encephalopathy, or fluid management problems. 
 Surprisingly, several pre-operative laboratory values were associated with readmission. 
Albumin, platelet count, and PT INR were all associated with readmission. As seen in the 
mortality model, decreasing albumin in decompensated cirrhotic patients is a clear predictor of 
health. As albumin falls, fluid management becomes more difficult, possibly leading to 
readmission. Platelet count and PT INR measures are associated with bleeding. Patients with 
cirrhosis have a difficult time with bleeding and surgery further complicates this delicate 
balance, possibly resulting in readmission. 
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 This study has several limitations evident in the results of the analyses. First, there 
is clear selection bias in the sample. Finding that pre-operative serum sodium was not predictive 
of mortality supports selection of healthier patients for surgery. In patients with liver cirrhosis, 
sodium has been found to be associated with mortality in multiple studies[56, 57]. 
 Second, for the readmission model, key factors may not be captured that are associated 
with readmission. This may introduce omitted variable bias in our model and decrease accuracy 
of the predictions (sensitivity/specificity/AUROC). Three such factors are socioeconomic status, 
home lifestyle factors, and insurance status of patients in our sample. Further studies are 
necessary to determine what factors are predictive of readmission and determine interventions to 
prevent readmission. 
 Finally, laboratory values were not missing completely at random or missing at random. 
This may have introduced bias into our models given we used complete case analysis. Further 
research in external samples is required to address the potential bias introduced by missing 
values. Imputation or selection models could have been undertaken but given the wide variation 
in laboratory values and missing information on hospitals or physicians in the dataset, they were 
not viable options.  
 Overall the readmission model performed reasonably well but did not reach the AUROC, 
sensitivity, and specificity goals of this study. Post-discharge patient-level data is required to 
accurately predict readmissions. Future studies will focus on collection of these factors to 
improve model performance. 
Next Steps 
This model will require substantial modification to improve performance moving 
forward. In fact, more development is required using post-discharge variables. Once the model is 
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fully developed and validated, it can be used to identify patients at greater risk of readmission 
and allocate at-home resources to these patients. One example may include scheduling more 
intensive home health visits for patients at greater risk of readmission. Prospective studies can 
assist in design of discharge plans tailored to the level of risk that successfully prevent unplanned 
readmissions. 
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CHAPTER 5. DISCUSSION AND FUTURE DIRECTIONS 
Discussion 
With the implementation of financial penalties for in-hospital mortality and 30-day 
readmissions by CMS, it is increasingly important to maximize value by reducing these costly 
events. To deliver high-quality care that reduces these penalties, it is necessary to predict which 
patients require more intensive in-hospital and post-discharge management. Predictive models 
are being used in health care to risk-stratify patients so that allocation of costly resources can be 
delivered to the right patients at the right time, resulting in better outcomes. This study develops 
and validates two predictive models that can help inform decisions for a high-risk population—
patients with decompensated liver cirrhosis undergoing surgical procedures. This study is the 
first to deliver such models for decompensated cirrhotic patients. 
Patients with decompensated cirrhosis are at greater risk of mortality due to sepsis, 
hepatic encephalopathy, and variceal hemorrhage[62]. Although sepsis is not unique to this 
population, hepatic encephalopathy and variceal hemorrhage are primarily seen in patients with 
cirrhosis. These comorbid conditions not only increase the risk of mortality but also the risk of 
readmission. Thus, specific models to predict mortality and readmissions in this population are 
necessary to capture these unique risk factors.  
 The National Surgical Quality Improvement Program (NSQIP) mortality model 
performance met the study goals and shows great promise for implementation in a real-world 
setting. Using secondary data to develop and internally validate models is a practical first step 
prior to its external validation and widespread implementation to make clinical decisions. In 
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addition to using the model to predict mortality, independent factors in the model shed light on 
potential opportunities to improve patient care. For example, the mortality model found hernia 
repair to have a protective effect. This may suggest that hernia repair is critical to reduce the 
decompensated patient’s risk of premature death. Further study is warranted on the benefits of 
hernia repair in this population. Additionally, the model found pre-operative albumin, total 
bilirubin, and Prothrombin International Normalized Ratio (PT INR) levels were strongly 
associated with mortality. For every one-point increase in the patient’s pre-operative albumin, 
mortality is reduced by 34% on average. Getting the albumin levels up in the cirrhotic patient 
prior to surgery may be critical in reducing the risk of post-operative mortality. The predictions 
from the mortality model were found to be informative in patients with a predicted probability of 
death between 10% and 76%. This is exactly where you want the model to be most useful. It is in 
patients that are in the middle range, not those with high or low risk of mortality, that the model 
is most needed to guide surgical decisions. When it is difficult for the surgeon, patient, and 
heptaologist to make the decision to proceed to surgery, the model is most informative and may 
better inform those decisions. Given the current paradigm is to use the MELD score to drive 
decisions in cirrhotic patients, this model is a much better option because it was significantly 
better than the MELD score at predicting post-surgical mortality. 
Although the NSQIP readmission model was reasonable, it did not meet the study 
performance goals. The inability of the readmission model to meet the study goals may be due 
inadequate sample size and/or the lack of information on patients once they leave the hospital. 
More often, consumer data is used to better understand patient behavior after discharge from a 
hospital. This model may benefit from addition of these factors in future development and 
validation efforts. In the current model, there were some useful findings. For example, insulin-
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dependent diabetes was a risk factor for readmission in decompensated cirrhotic patients. Better 
management of diabetes after surgery may be required for these patients. Implementing more 
intensive home health services for insulin-dependent diabetics may be one strategy for reducing 
readmission. If serum pre-operative albumin is increased by one point prior to surgery, there is a 
21% decrease in the risk of post-surgical readmission. The albumin levels can be managed pre-
operatively to reduce the risk of readmission in these patients. Predictions from the full model 
can guide the intensity of discharge planning. The model did outperform the Model for End 
Stage Liver Disease (MELD) score and may be a better way to assess risk of readmission in this 
population. 
 Both models are a strong starting point for improving the quality of care patients with 
cirrhosis receive. By implementing predictive models such as these in the electronic medical 
record (EMR) clinicians will be better able to judge risk of mortality or readmission. The current 
paradigm is for a hepatologist and surgeon to discuss a patient’s risk of mortality using the 
MELD score, clinical comorbidities, and many other factors (patient compliance, insurance 
status). MELD scores are inadequate for predicting risk of death or readmission across a broad 
range of patients with cirrhosis. These NSQIP models give a concrete risk score to the clinician 
that can better inform the decision-making process.  
Hospital discharge teams would benefit from knowing the risk of readmission in this 
special population of decompensated cirrhotic patients. Fluid management and keeping albumin 
levels in the up is key in patients with decompensated cirrhosis, especially after surgery. This 
model identifies that for those at greater risk of readmission and home health services, remote 
weight monitoring, albumin supplementation, and giving a 30-day supply of medication at 
discharge may all be strategies that can be implemented based on the readmission risk score. To 
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implement these interventions for everyone with decompensated cirrhosis, without knowing the 
risk of readmission, would be too costly.  
 Overall, both the mortality and readmission models move clinical care for patients with 
cirrhosis forward. First, prior to this study, no model existed to predict mortality or readmissions 
in decompensated cirrhotic patients. Second, the MELD score is overused for decision making 
when caring for patients with cirrhosis. It has multiple limitations that these models overcome. 
Last, targeted interventions can be investigated using the risk score to stratify patients into 
specific clinical care plans. 
 After further validation of each model using real-world clinical data, it is possible to 
implement the models in a widely used electronic medical record system such as Epic™. Epic™ 
Web is an Epic™ data warehouse for user-developed programs and registries that can be 
implemented by sites. It is possible to post models to the Epic™ Web after further validation. 
This is beyond the scope of this dissertation.  
The models may be implemented as smartphone applications in addition to Epic™ 
programs. This would allow non-Epic™ users to access the programs easily in the clinical 
environment regardless of the electronic medical record system in use at their facility. 
Both mortality and readmission models will require further study prior to using in the 
real-world setting. My first priority is to work with the Carolina Data Warehouse at the 
University of North Carolina to implement the mortality model for further validation. Being able 
to get a risk score for patients undergoing any type of surgery with both compensated and 
decompensated liver cirrhosis will broaden the scope of the model. Following patients outcomes 
will be easy considering the goal is to prevent in-hospital mortality after the surgical procedure. 
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My second priority is to improve the readmission model by obtaining information on 
patients once discharged. There are several initiatives underway at UNC Healthcare to prevent 
readmissions and better manage population health. One such initiative is to use consumer data on 
patients to gain better insight into their at-home habits to improve readmission prediction. I am 
very interested in novel data sources that may work to improve the model in this particular 
population of cirrhotic patients. I plan to collaborate with the UNC Healthcare population 
management data scientists to build a better model. 
Two papers will be produced from the dissertation, one each for the NSQIP mortality and 
NSQIP readmission models. I plan to submit both papers to clinical journals such as 
Gastroenterology and Clinical Gastroenterology and Hepatology. Additionally, I plan to submit 
abstracts to the American College of Gastroenterology (ACG) and American Association for the 
Study of Liver Diseases (AASLD) meetings in 2015. 
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APPENDIX. TABLES AND FIGURES 
Table 1. Model Measures and Justification 
Measures Description Theory Behind Selection 
Specific 
Aims 
Age 
Patient’s age at time of 
surgery  
Control for declining 
kidney and liver function 
due to age[7] 
All aims 
Gender 
Male/Female Control for differences in 
creatinine between 
genders[40, 41] 
All aims 
Pre-operative 
Body Mass Index 
(BMI) 
Using height and weight from 
the data: 
BMI=[mass(lbs)/height (in)^2 
] x 703 
Risk of mortality is 
increased in moribund 
patients[63-65] 
All aims 
Pre-operative 
Functional Status 
Functional status assessment 
prior to surgery: 
1-independent  
2-partially dependent 
3-Totally dependent 
Controls for poor health 
status prior to surgery. 
Those with lower 
functional status may carry 
greater risk of mortality 
pre-operatively[66] 
All aims 
Ethnicity/Race 
African 
American/White/Asian/Other 
Control for differences 
across ethnicities 
All aims 
Pre-operative 
estimated 
Glomerular 
Filtration Rate 
(eGFR) 
Use of the 2005 modification 
of diet and renal disease 
(MDRD*) formula: eGFR= 
186 x SCr
-1.154
 x Age
-0.203
 x 
[1.210 if Black] x [0.743 if 
Female] 
 
Captures early acute 
kidney injury often due to 
fluid overload from 
decompensated 
cirrhosis[40] 
All aims 
Pre-operative 
Serum Albumin 
Measured in g/dL Made by the liver and 
captures biosynthetic liver 
function-declines as liver 
function declines in 
cirrhosis[33] 
All aims 
Pre-operative 
Platelet Count 
Measured in mmol/L Hyponatremia (i.e., low 
sodium) associated with 
mortality across multiple 
conditions[35] 
All aims 
Pre-operative 
White Blood Cell 
Count (WBC) 
May be indicative of pre-
operative infection or 
inflammation 
Has been shown counts 
>10,000 are associated 
with a high mortality rate 
of 54% versus 19% in 
intra-abdominal surgery in 
patients with cirrhosis of 
any etiology[67] 
All aims 
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Pre-operative 
Serum Total 
Bilirubin 
Measured in mg/dL Captures biosynthetic liver 
function. Increases with 
cellular damage in the 
liver[67]  
All aims 
Pre-operative 
Prothrombin INR 
INR(international normalized 
ratio): standard measure of the 
clotting capacity of blood 
May detect risk of post-
surgical bleeding as well as 
capture liver function[68] 
All aims 
Emergency 
Surgery 
Surgery was due to emergent 
condition 
Controls for a greater 
probability of mortality due 
to an emergent 
condition[67] 
All aims 
Type of Surgery 
Surgical types include:  
1) Cardiothoracic 
 2) General 
3) Other-not classified 
elsewhere 
4) Laparoscopic procedures 
 5) Cholecystectomy (lap or 
open) 
6) Open abdominal  
7) Hernia Repair (lap or open) 
 
Controls for type of 
surgery[9]  
All aims 
Comorbidities 
Includes: 
1) Diabetes (Oral medication, 
Non-insulin or injectable 
insulin dependent) 
Control for comorbidities 
that may increase the risk 
of post-surgical 
mortality[69-72]  
All aims 
American Society 
of 
Anesthesiologists 
Physical Status 
Classification 
(ASA class) 
 Healthy patient 
 Mild systemic disease-
no functional 
limitation 
 Severe systemic 
disease-definite 
functional limitation 
 Severe systemic 
disease that is a 
constant threat to life 
 Moribund-patient is 
not expected to 
survive without 
surgery 
ASA classification is 
associated with post-
operative moratlity when 
used pre-operatively to 
stratify risk in patients[73] 
All aims 
Duration of 
Anesthesia and 
Duration of 
Operation 
Total duration of surgery from 
anesthesia start to anesthesia 
stop (minutes) 
Greater time in surgery 
increases risk of 
readmission due to 
complications[74] 
2a, 2b, 2c 
Post-operative Patient developed pneumonia Risk of readmission is 2a, 2b, 2c 
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Pneumonia based on radiology or 
laboratory data 
greater if post-operative 
pneumonia developed[75] 
Post-operative 
Sepsis or Septic 
Shock 
Patient developed sepsis or 
septic shock. 
Patients with cirrhosis are 
at greater risk of sepsis[12, 
75] 
2a, 2b, 2c 
Post-operative 
Acute or 
Progressive Renal 
Failure 
Patient developed either acute 
or progressive renal failure. 
Patients with 
decompensated cirrhosis 
are at greater risk of acute 
renal failure[76, 77] 
2a, 2b, 2c 
Post-operative 
Urinary Tract 
Infection 
Patient developed urinary 
tract infection. 
Urinary tract infection 
increases the risk of 
readmission[75] 
2a, 2b, 2c 
Post-operative 
Unplanned 
Intubation 
Patient was removed from 
ventilator and re-intubated. 
Complication resulted in an 
unplanned reintubation 
may increase risk of 
readmission[78] 
2a, 2b, 2c 
Post-operative  
Failure to Wean 
from Ventilator 
On ventilator >48 hours 
Extended time on the 
ventilator is associated 
with greater risk of 
mortality, length of stay 
and pneumonia[79] 
 
2a, 2b, 2c 
 
 
 
Discharge 
Destination 
 
1-Skilled care, not home 
2- Unskilled facility, not 
home. 
3-Same pre-operative facility 
4-Home 
5-Separate acute care 
6- Rehabilitation facility 
 
Discharge destination has 
been associated with the 
odds of readmission[4] 
2a, 2b, 2c 
Total Length of 
Hospital stay 
Days 
Risk of secondary 
nosocomial infection 
may increase as length 
of hospital stay 
increases[80] 
2a, 2b, 2c 
Abbreviations: *MDRD=Modification of Diet in Renal Disease eGFR equation 
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Table 2. Surgical Categories 
 
Surgery Type Description 
Cardiothoracic Surgeries requiring cutting into the thoracic cavity. 
General Surgery Surgeries not classified as cardiothoracic or abdominal. 
Open Abdominal 
Any surgery requiring cutting into the abdominal wall 
excluding hernia repair and cholecystectomy 
Any 
Laparoscopic 
Procedure 
Any laparoscopic procedure excluding lap 
cholecystectomy or lap hernia repair. 
Cholecystectomy Any cholecystectomy (lap or open) 
Hernia Repair Any hernia repair (lap or open) 
Other-not 
classified 
elsewhere 
Surgeries not classified elsewhere 
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Table 3. Summary of Model Performance Measures 
Measure Statistic Interpretation Expected  
Value 
Overall model 
performance 
Brier Score Range: 0-0.25  
Lower scores indicate better 
calibration and discrimination. 
<=0.25 (given 
50% chance of 
death) 
Discrimination AUROC, Sensitivity, 
Specificity, Positive 
Predictive Value, Negative 
Predictive Value, % correctly 
classified  
 
Note: all measures are at a 
specified cut-point 
AUROC: Plots sensitivity (SN)* vs. 
1-specificity (SP)**. Range 0-1 with 
scores closer to 1 indicating better 
discrimination. 
 
Sensitivity: Ability of the model to 
identify true positives correctly at a 
specific cut-point 
 
Specificity: Ability of the model to 
identify true negatives at a specific 
cut-point 
AUROC>0.80 
 
 
 
 
Sensitivity>80% 
Specificity>80% 
Calibration Calibration-in-the Large 
 
Calibration-in-the Small 
 
Hosmer-Lemeshow 
Goodness-of-fit Test 
Taking the square root of the 
calibration-in-the-large gives the % 
difference between the predictive 
fraction of positive results versus 
the predicted fraction of negative 
results.  
 
The square root of the calibration-
in-the small gives the % difference 
between the predictive positives 
and negatives versus the actual 
fraction amongst the groups. 
 
The Hosmer-Lemeshow goodness-
of-fit test is an indicator of how well 
my model fits the data in my 
sample. It indicates if the model is 
correctly specified. To simplify, is 
the actual number of patients that 
died or were readmitted match the 
predicted numbers. Hosmer-
Lemeshow breaks the groups into 
10 different groups of fitted values. 
If p>0.05 then we can assume our 
model’s predictions are similar to 
the actual outcome across 10 
different areas of the range of 
probabilities. 
 
 
<5% difference 
 
 
 
 
 
 
<5% difference 
 
 
 
 
p>0.05 (accept 
model is 
correctly 
specified) 
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Cross-
Validation 
AUROC for both the k-fold 
analysis and the leave-one-
out analysis 
Predicts the ability of the model to 
maintain performance in an 
external dataset.  
 
k-fold: fold data into 10 smaller 
training/validation sets. 
 
Leave-one-Out: use entire set to 
train and apply to the observation 
left out. Continue until you have 
predicted all observations. 
AUROC>0.80 
 
*SN=true positives/(true positives(TP) + false negatives(FN)) 
**SP= true negatives/(true negatives(TN) + false positives(FP)) 
 
 
 
 
Table 4. Sample Size Requirements for the Mortality and Readmission Cohorts 
Cohorts Incidence Power Alpha 
Sample 
Size* 
Required 
(Sensitivity) 
Sample Size 
Required* 
(Specificity) 
Mortality 
Cohort 
12.36% 80% 0.05 1,989 281 
Readmissions 
Cohort 
13.14% 80% 0.05 1,871 283 
*The sample sizes are sufficient for all aims. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5. Bivariate Analyses 
Mortality Cohort   Unplanned Readmission Cohort 
Variable Overall 
Discharged 
Alive Died In-house 
p-value 
  Overall 
Unplanned 
Readmission 
No 
Readmission 
p-value   n=4,535 n=3,927 n=608   n=3,475 n=542 n=2,933 
     
  
    Age (%)  
    
  
    <40 6.9 7.2 5.1 0.06   7.5 7.3 8.1 0.52 
41-50 13.2 13.7 10.2 0.02*   14.4 14.2 15.7 0.37 
51-60 28.9 29.4 26.2 0.1   30.9 30.7 32.3 0.46 
61-70 26.9 26.5 28.9 0.21   27 27.2 25.6 0.44 
71-80 15.1 14.5 19.1 0.004*   13.4 13.5 12.7 0.64 
>80 8.9 8.7 10.5 0.14   6.8 7.1 5.5 0.2 
     
  
    Race (%)  
    
  
    White 75 75.5 71.9 0.06   76.7 76.7 76.8 0.96 
Black 12 12.2 11.4 0.59   11.5 11.1 13.5 0.11 
Other 12.9 12.4 16.7 0.003   11.7 12.1 9.6 0.1 
     
  
    Gender (%) 
    
  
    Female 42.4 42.3 43.1 0.71   43.2 43.3 42.4 0.7 
Male 57.6 57.7 56.9 0.71   56.8 56.7 57.6 0.7 
     
  
    Chronic Kidney Disease
Stage (%) 
    
  
    I. Normal 30.1 32.2 16.5 <0.001**   34.7 34.8 33.9 0.68 
IIa. Some kidney 
damage 26.6 28 17.4 <0.001**   28.8 29.1 26.7 0.26 
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 IIb. Moderate kidney 
damage 23.6 23 27.5 0.01*   22.4 22.4 22.3 0.99 
III. Severe kidney 
damage 11.3 9.2 24.9 <0.001**   7.5 7.2 8.7 0.24 
Kidney Failure 8.5 7.7 13.7 <0.001**   6.7 6.4 8.3 0.1 
     
  
    Emergent surgery (%) 43.5 39.3 70.6 <0.001**   36.5 36.7 35.2 0.51 
     
  
    Pre-operative
Comorbidities & 
Procedures (%) 
    
  
    Confusion (proxy for 
encephalopathy) 9.2 5.5 30 <0.001**   5.8 5.8 5.9 0.96 
Alcohol use 8.2 7.2 13.7 0.003*   7.4 7.1 8.9 0.42 
Chronic obstructive 
pulmonary disease 10 9.3 14.5 <0.001**   8.8 9.1 7.2 0.14 
Peripheral Vascular 
Disease 4.6 4.2 6.3 0.21   4.4 4.5 3.6 0.57 
Chronic Heart Failure 8 7 14.5 <0.001**   6.4 6.3 6.6 0.77 
Smoker 27.6 27.4 28.8 0.47   28.9 28.9 28.6 0.88 
     
  
    Diabetic Status (%) 
    
  
    Not diabetic 74.6 74.8 72.9 0.3   75.6 76.8 69.0 <0.001** 
Insulin dependent 15.8 15.5 17.8 0.15   14.7 13.8 19.6 <0.001** 
Non-Insulin dependent 9.7 9.7 9.4 0.78   9.7 9.3 11.4 0.13 
     
  
    Pre-operative
transfusion required 
(%) 15.8 13.7 29.3 <0.001**   11 10.9 11.4 0.74 
     
  
    Type of Surgery (%) 
    
  
    Open Abdominal 9.2 10.2 3.3 <0.001**   10.1 10.3 9.2 0.45 
Cardiothorasic 7.1 7.2 6.6 0.59   5.1 5.1 5.2 0.96 
5
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 General surgery 46.0 43.4 63.0 <0.001**   43.4 43 45.6 0.27 
Other surgery type-not 
specifi 2.2 2.3 2.1 0.84   2.2 2.1 3 0.21 
Any lapararoscopic 
procedure 11.4 10.4 17.8 <0.001**   10.6 10.8 9.2 0.27 
Cholecystectomy 5.2 5.6 2.5 0.001*   5.2 5.4 4.4 0.37 
Hernia repair 18.8 21.0 4.8 <0.001**   23.4 23.4 23.4 0.97 
     
  
    BMI Category (%) 
    
  
    Normal 34.3 34.6 32 0.22   35.8 35.1 39.5 0.05 
Underweight 4.9 4.6 7.1 0.01*   4.6 4.3 5.8 0.13 
Overweight 29.8 30.7 23.7 <0.001**   31 31.5 28.6 0.19 
Obese 31 30.1 37.3 <0.001**   28.6 29.1 26 0.14 
     
  
    Functional Status (%) 
    
  
    Independent 85 87.7 66.8 <0.001**   88.3 88.5 87.2 0.41 
Partially Dependent 9.8 8.7 16.8 <0.001**   8.4 8.2 9.3 0.43 
Totally Dependent 5.3 3.6 16.3 <0.001**   3.3 3.3 3.5 0.8 
     
  
    ASA Class 
    
  
    Mild Disturb 8 9.1 1.3 <0.001**   9.9 10.4 7.6 0.05 
Severe Disturb 46.5 50.7 19 <0.001**   53.5 53.7 52.8 0.7 
Life Threat 40 36.5 62.6 <0.001**   34.6 33.8 38.9 0.02* 
Moribund 5.5 3.7 17 <0.001**   1.9 2.1 0.7 0.03* 
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 Pre-Operative 
Laboratory Values                  
[Median (25th, 75th 
percentile] 
    
  
    
Albumin 
2.8             
(2.2,3.4) 
2.9            
(2.3,3.4) 
2.4          
(1.9,2.9) <0.001**   
2.9            
(2.4,3.5) 
2.9                         
(2.1,3.5) 
2.8                      
(2.3,3.4) 0.001* 
Sodium 
137         
(134,140) 
137           
(134,140) 
137         
(133,141) 0.77   
137         
(134,140) 
137                
(134,140) 
136            
(133,139) 0.001* 
Total Bilirubin 
1.0             
(0.5,1.9) 
0.9            
(0.5,1.7) 
1.6            
(0.8,3.4) <0.001**   
0.9           
(0.5,1.8) 
0.9                   
(0.5,1.7) 
1.0               
(0.5,2.1) 0.003* 
Platelets  
145            
(91,254) 
148           
(94,259) 
134           
(75,218) <0.001**   
179        
(103,280) 
182                
(106,283) 
155              
(91,263) 
<0.001*
* 
PT INR 
1.3             
(1.1,1.6) 
1.3            
(1.1,1.6) 
1.5            
(1.2,1.9) <0.001**   
1.2           
(1.1,1.4) 
1.2                   
(1.1,1.4) 
1.3              
(1.1,1.5) 0.005* 
White Blood Cell count 
7.9           
(5.2,12.4) 
7.6          
(5.0,11.5) 
11.8         
(7.2,18.7) <0.001**   
7.6         
(5.0,11.3) 
7.6                        
(5.1, 11.4) 
7.2            
(4.8,10.5) 0.03* 
estimated glomerular 
filtration rate (eGFR)                                                       
[Median (25th, 75th 
percentile] 
67.2             
(36.3, 97.0) 71.1 (41.2,98.9) 
40.0 
(22.2,72.4) <0.001**   
73.8 
(45.5,101.7) 
74.1           
(46.1,101.8) 
71.5 
(41.6,101.3) 0.17 
     
  
    MELD Category (%) 
    
  
    MELD <=9 23.7 26.0 8.0 <0.001**   30.1 31.1 24.5 0.002** 
MELD 10-19 51.9 53.3 41.7 <0.001**   53.6 53.4 54.4 0.66 
MELD 20-29 19.1 16.4 37.9 <0.001**   13.6 12.8 18.3 
<0.001*
* 
MELD 30-39 4.9 4.0 11.1 <0.001**   2.6 2.6 2.6 >0.99 
MELD >40 0.4 0.3 1.2 <0.001**   0.1 0.1 0.2 0.79 
     
  
    Childs-Pugh Category
(%) 
    
  
    CTP A 6.5 7.1 3.0 <0.001**   4.6 4.7 4.1 0.49 
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 CTP B 29.3 31.7 14.0 <0.001**   23.9 24.6 20.1 0.02* 
CTP C 64.1 61.2 83.1 <0.001**   71.5 70.7 75.8 0.01* 
    
.   
    APRI score                                                           
[Median (25th, 75th 
percentile] 
0.6            
(0.3,1.6) 
0.6            
(0.3,1.4) 
1.1           
(0.5,3.0) <0.001**   
0.5           
(0.2,1.3) 
0.5                   
(0.2,1.2) 
0.6                
(0.3,1.7) 
<0.001*
* 
Total Length of Stay in 
Days                                                                           
[Median (25th, 75th 
percentile] 
10                
(4,20) 
9                   
(4,19) 
14                 
(6,26) <0.001**   
9                   
(4,19) 
9                         
(4,20) 
10                    
(5,16) 0.17 
*P<0.05 
**P<0.001 
Mortality and Readmission cohorts include only patients with laboratory values available to generate both the MELD score and the Moratlity/Readmission 
models. 
P-values by non-parametric test for trend 
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Table 6. Comparison of the Cirrhotic Cohort with and without Laboratory Values 
Cirrhotic Cohort 
Variable Overall 
Missing 
Laboratory 
Values 
All laboratory 
values 
available for 
models 
p-value   n=4,916 n=273 n=4,643 
Year of Operation 
    2011 31.4 31.1 31.4 0.93 
2012 28.1 24.5 28.3 0.18 
2013 40.5 44.3 40.3 0.19 
     Age  
    <40 6.9 7.7 6.8 0.57 
41-50 13.1 14.3 13.0 0.54 
51-60 28.6 24.9 28.9 0.16 
61-70 26.8 26.7 26.8 0.98 
71-80 15.4 17.2 15.3 0.39 
>80 9.2 9.2 9.2 0.96 
     Race  
    White 75.8 69.6 76.2 0.03* 
Black 11.3 8.3 11.5 0.15 
Other 12.9 22.1 12.4 <0.001** 
     Gender 
    Female 42.2 43.6 42.2 0.64 
Male 57.8 56.4 57.8 0.64 
     
     Emergent surgery 43.9 56.4 43.1 <0.001** 
     Pre-operative Comorbidities & Procedures 
    Confusion (proxy for encephalopathy) 9.5 19.4 9.0 0.003** 
Alcohol use 8.1 6.9 8.2 0.7 
Chronic obstructive pulmonary disease 10.0 11.0 10.0 0.59 
Peripheral Vascular Disease 4.6 0.0 4.8 0.06 
Chronic Heart Failure 8.1 11.7 7.8 0.02* 
Smoker 27.8 28.9 27.7 0.66 
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Diabetic Status (%) 
    Not diabetic 74.5 76.2 74.4 0.5 
Insulin dependent 15.9 15.0 15.9 0.69 
Non-Insulin dependent 9.7 8.8 9.7 0.62 
     Pre-operative transfusion required (%) 15.7 23.4 15.2 <0.001** 
     Type of Surgery (%) 
    Open Abdominal 9.3 10.6 9.2 0.44 
Cardiothorasic 7.3 8.4 7.2 0.45 
General surgery 45.8 41.0 46.1 0.1 
Other surgery type-not specifi 2.4 2.9 2.3 0.52 
Any lapararoscopic procedure 11.5 21.6 10.9 <0.001** 
Cholecystectomy 5.2 3.3 5.3 0.15 
Hernia repair 18.6 12.1 19.0 0.005* 
     BMI Category (%) 
    Normal 34.5 29.9 34.8 0.12 
Underweight 4.9 5.3 4.9 0.76 
Overweight 29.6 29.1 29.7 0.85 
Obese 30.9 35.7 30.7 0.1 
     Functional Status (%) 
    Independent 84.7 82.3 84.8 0.27 
Partially Dependent 9.9 6.8 10.1 0.08 
Totally Dependent 5.5 10.9 5.1 <0.001** 
     ASA Class 
    Mild Disturb 7.7 4.1 7.9 0.02* 
Severe Disturb 45.8 30.4 46.7 <0.001** 
Life Threat 40.7 47.8 40.2 0.01* 
Moribund 5.8 17.8 5.1 <0.001** 
     
     
Total Length of Stay in Days                            
[Median (25th, 75th percentile] 
10
(4,20) 
11                         
(4,19) 
10                      
(4,20) >0.99 
*P<0.05 
**P<0.001 
P-values by non-parametric test for trend 
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Table 7. Poisson Model for In-hospital Mortality (N=1,834) 
Variable IRR Robust SE Z p-value 
95% CI 
Low High 
Age 
      41-50 1.437 0.318 1.640 0.101 0.932 2.216 
51-60 1.485 0.295 1.990 0.047* 1.005 2.192 
61-70 2.047 0.407 3.600 <0.001** 1.386 3.022 
71-80 2.186 0.458 3.730 <0.001** 1.450 3.295 
>80 2.382 0.540 3.830 <0.001** 1.528 3.713 
       Male (ref. female) 1.006 0.085 0.070 0.948 0.852 1.186 
       BMI (ref. Normal) 
      Underweight 1.310 0.214 1.660 0.097 0.952 1.803 
Overweight 0.887 0.101 -1.050 0.294 0.709 1.110 
Obese 1.065 0.104 0.650 0.517 0.880 1.290 
       
       Functional Status (ref:
Independent) 
      Partially Dependent 1.365 0.161 2.630 0.009* 1.083 1.720 
Totally Dependent 1.384 0.148 3.040 0.002* 1.122 1.707 
       ASA Class (ref: Mild
Disturbance)  
      Life Threat 4.030 1.541 3.650 <0.001** 1.905 8.525 
Moribund 5.478 2.159 4.310 <0.001** 2.530 11.862 
       Race (ref: White) 
      Black 0.994 0.126 -0.050 0.963 0.776 1.274 
Other 0.974 0.115 -0.220 0.824 0.773 1.228 
       estimated glomerular
filtration rate (eGFR) 0.997 0.001 -2.030 0.043* 0.995 1.000 
Albumin 0.801 0.044 -4.050 <0.001** 0.719 0.892 
Sodium 1.004 0.007 0.540 0.590 0.990 1.017 
Platelet count 0.999 0.000 -2.810 0.005* 0.998 1.000 
White blood cell 
count 1.007 0.004 1.660 0.097 0.999 1.016 
Total bilirubin 1.100 0.012 8.800 <0.001** 1.077 1.124 
PT INR 1.274 0.059 5.220 <0.001** 1.164 1.396 
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       Emercenty surgery 1.698 0.187 4.810 <0.001** 1.368 2.107 
       Diabetic Status (ref:
Non-diabetic) 
      Insulin dependent 0.854 0.093 -1.460 0.145 0.690 1.056 
Non-insulin dependent 0.933 0.130 -0.500 0.618 0.710 1.226 
       Chronic obstructive
pulmonary disease 1.001 0.114 0.010 0.995 0.800 1.251 
Chronic Heart Failure 1.179 0.125 1.560 0.119 0.958 1.451 
       Surgery Type (ref:
Open Abdominal) 
      Cardiothorasic 1.484 0.459 1.280 0.202 0.809 2.721 
General surgery 1.303 0.345 1.000 0.317 0.776 2.188 
Other surgery type-
not specified 1.032 0.453 0.070 0.943 0.437 2.438 
Any lapararoscopic 
procedure 1.450 0.401 1.350 0.178 0.844 2.492 
Cholecystectomy 1.118 0.398 0.310 0.754 0.556 2.247 
Hernia repair 0.468 0.159 -2.230 0.025* 0.241 0.911 
       _cons 0.014 0.015 -3.850 0.000 0.002 0.121 
*P<0.05 
**P<0.001 
 
  
63 
Table 8. Logit Model for In-Hospital Mortality (N=1,945) 
Variable Odds Ratio Robust SE Z p-value 
95% CI 
Low High 
Age (ref: <=40)             
41-50 1.799 0.639 1.650 0.098 0.897 3.609 
51-60 2.041 0.666 2.190 0.029* 1.077 3.868 
61-70 3.519 1.165 3.800 <0.001** 1.839 6.733 
71-80 3.688 1.297 3.710 <0.001** 1.851 7.349 
>80 4.385 1.666 3.890 <0.001** 2.083 9.232 
  
     
  
Race (ref: White) 
     
  
Black 1.011 0.206 0.050 0.958 0.678 1.507 
Other 1.071 0.202 0.370 0.714 0.741 1.549 
  
     
  
Functional Status (ref: 
Independent) 
     
  
Partially 1.731 0.323 2.940 0.003* 1.201 2.496 
Totally 2.171 0.426 3.950 <0.001** 1.478 3.189 
  
     
  
ASA Class (ref: Mild 
Disturbance)  
     
  
Life Threat 3.563 1.443 3.140 0.002* 1.611 7.881 
Moribund 8.802 3.915 4.890 <0.001** 3.681 21.047 
  
     
  
Comorbidities 
     
  
Chronic Heart Failure 1.185 0.229 0.880 0.379 0.812 1.731 
Chronic Obstructive 
Pulmonary Disease 1.060 0.191 0.320 0.747 0.744 1.510 
  
     
  
Diabetic status (ref: Non-
diabetic) 
     
  
Insulin 0.727 0.125 -1.860 0.063 0.519 1.017 
Non-Insulin 0.882 0.192 -0.580 0.564 0.575 1.352 
  
     
  
Pre-Operative Laboratory 
Values 
     
  
estimated glomerular 
filtration rate (eGFR) 0.997 0.002 -1.730 0.084 0.994 1.000 
Albumin 0.658 0.057 -4.840 <0.001** 0.555 0.779 
Platelet Count 0.999 0.001 -2.160 0.031* 0.997 1.000 
Total Bilirubin 1.229 0.036 6.980 <0.001** 1.160 1.302 
PT INR 1.873 0.246 4.790 <0.001** 1.449 2.422 
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Emergency surgery (ref: 
Scheduled) 2.239 0.338 5.350 <0.001** 1.666 3.010 
  
     
  
Surgery Type (ref: Open 
Abdominal) 
     
  
Cardiothorasic 1.950 0.831 1.570 0.117 0.845 4.497 
General surgery 1.467 0.536 1.050 0.294 0.717 3.004 
Other surgery type-not 
specified 1.015 0.586 0.030 0.980 0.327 3.147 
Any lapararoscopic 
procedure 1.932 0.752 1.690 0.091 0.901 4.142 
Cholecystectomy 1.009 0.529 0.020 0.986 0.362 2.817 
Hernia repair 0.349 0.151 -2.430 0.015* 0.149 0.815 
  
     
  
_cons 0.015 0.011 -5.950 0.000 0.004 0.060 
*P<0.01 
**P<0.001 
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Table 9. Mortality Model Validation Summary 
Calibration  
     Calibration -in-the-Large 0.0004 
    Calibration-in-the-Small 0.0014 
    Hosmer-Lemeshow 
Goodness-of-fit  (chi^2 test) 8.97 p=0.345 
   
      Discrimination 
     AUROC 0.8282 
    Sensitivity (cut-point=0.2150) 81.10% 
    Specificity (cut-point=0.2150) 73.60% 
    Positive Predictive Value 
(cut-point=0.2150) 47.60% 
    Negative Predictive Value 
(cut-point=0.2150) 92.90% 
    Correctly Classified 75.30% 
    
      Out-of-Sample performance  
     
 
AUROC 
    K-fold (k=10) method 0.8402 
    Leave-one-out method 0.8420 
    
      Overall Model Performance 
     Brier Score 0.1269 
    
      Cut-Point Performance  
     Cutpoint Sensitivity Specificity Classified LR+ LR- 
0.149 88.96% 60.83% 67.25% 2.271 0.1814 
0.150 88.29% 61.09% 67.30% 2.2692 0.1917 
0.160 86.71% 62.82% 68.28% 2.3325 0.2115 
0.170 85.14% 65.09% 69.67% 2.4387 0.2284 
0.180 84.01% 67.42% 71.21% 2.5787 0.2372 
0.190 83.78% 68.62% 72.08% 2.6701 0.2363 
0.200 82.66% 70.95% 73.62% 2.8456 0.2444 
0.215 81.08% 73.55% 75.27% 3.0656 0.2572 
0.300 67.12% 82.74% 79.18% 3.8897 0.3974 
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Table 10. Poisson Model for Readmission within 30-days of the Index Surgery (N=1,495) 
Variable IRR Robust SE Z p-value 
95% CI 
Low High 
Age (ref: <=40) 
      41-50 1.061 0.255 0.250 0.805 0.663 1.698 
51-60 0.851 0.188 -0.730 0.466 0.552 1.313 
61-70 0.790 0.177 -1.050 0.293 0.509 1.226 
71-80 0.775 0.208 -0.950 0.343 0.458 1.312 
>80 0.818 0.257 -0.640 0.522 0.442 1.513 
       Male (ref. female) 0.789 0.097 -1.930 0.054 0.619 1.004 
       BMI (ref. Normal) 
      Underweight 0.813 0.226 -0.740 0.457 0.472 1.402 
Overweight 0.806 0.112 -1.550 0.121 0.614 1.058 
Obese 0.789 0.117 -1.600 0.109 0.591 1.054 
       Functional Status (ref:
Independent) 
      Partially Dependent 0.737 0.170 -1.320 0.187 0.469 1.159 
Totally Dependent 1.374 0.339 1.290 0.198 0.847 2.229 
       ASA Class (ref: Mild
Disturbance)  
      Life Threat 1.628 0.302 2.630 0.009* 1.132 2.342 
Moribund 0.721 0.377 -0.630 0.531 0.259 2.006 
       Race (ref: White) 
      Black 1.157 0.186 0.910 0.364 0.844 1.586 
Other 0.936 0.190 -0.330 0.743 0.629 1.393 
       Pre-operative
Laboratory Values 
      estimated glomerular 
filtration rate (eGFR) 0.999 0.001 -0.910 0.365 0.996 1.001 
Albumin 0.853 0.069 -1.970 0.049* 0.728 0.999 
Sodium 0.989 0.013 -0.860 0.388 0.964 1.014 
Platelet count 0.999 0.001 -1.930 0.054 0.998 1.000 
White blood cell count 1.008 0.010 0.750 0.452 0.988 1.028 
Total bilirubin 0.990 0.032 -0.300 0.767 0.929 1.056 
PT INR 1.480 0.193 3.010 0.003* 1.146 1.911 
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Emercency surgery 0.930 0.134 -0.500 0.615 0.702 1.233 
       Diabetic Status (ref:
Non-diabetic) 
      Insulin dependent 1.617 0.232 3.360 0.001* 1.221 2.141 
Non-insulin dependent 1.048 0.220 0.230 0.822 0.695 1.581 
       Surgery Type (ref: Open
Abdominal) 
      Cardiothorasic 0.986 0.282 -0.050 0.959 0.563 1.726 
General surgery 1.119 0.259 0.480 0.628 0.711 1.760 
Other surgery type-not 
specified 1.285 0.408 0.790 0.429 0.690 2.393 
Any lapararoscopic 
procedure 1.258 0.346 0.840 0.403 0.734 2.157 
Cholecystectomy 0.581 0.243 -1.300 0.194 0.256 1.318 
Hernia repair 0.780 0.202 -0.960 0.336 0.469 1.295 
       Post-Operative
Variables 
      Pneumonia 1.032 0.397 0.080 0.935 0.485 2.195 
Sepsis 1.966 0.301 4.410 <0.001** 1.456 2.656 
Time on Table 1.002 0.001 3.040 0.002* 1.001 1.003 
Time from operation to 
discharge 0.932 0.011 -5.760 <0.001** 0.910 0.955 
Acute or Progressive 
Renal Failure 1.570 0.330 2.150 0.032* 1.041 2.369 
Urinary Tract Infection 2.225 0.514 3.460 0.001* 1.415 3.499 
On Ventilator >48 hrs 0.760 0.154 -1.350 0.175 0.511 1.130 
Unplanned intubation 1.518 0.305 2.080 0.038* 1.024 2.250 
       Discharge Destination 
      Home 1.210 0.203 1.140 0.256 0.871 1.682 
Rehab 0.550 0.172 -1.910 0.056 0.298 1.016 
Separate Acute Care 0.492 0.223 -1.560 0.118 0.202 1.196 
       Total Hospital Length of
Stay 1.006 0.009 0.730 0.466 0.990 1.023 
_cons 0.993 1.866 0.000 0.997 0.025 39.506 
*P<0.01, **P<0.001 
 
 
  
68 
Table 11. Logit Model for Readmission within 30-days of the Index Surgery (N=1,495) 
Variable OR Robust SE Z p-value 
95% CI 
Low High 
Age (ref: <=40) 
      41-50 1.039 0.344 0.110 0.909 0.543 1.988 
51-60 0.788 0.240 -0.780 0.435 0.433 1.433 
61-70 0.699 0.215 -1.170 0.244 0.383 1.276 
71-80 0.661 0.241 -1.140 0.256 0.324 1.349 
>80 0.693 0.287 -0.880 0.377 0.308 1.562 
       Male (ref. female) 0.705 0.120 -2.050 0.041* 0.504 0.985 
       BMI (ref. Normal) 
      Underweight 0.763 0.275 -0.750 0.453 0.376 1.548 
Overweight 0.769 0.143 -1.410 0.159 0.534 1.108 
Obese 0.729 0.146 -1.590 0.113 0.493 1.078 
       Functional Status (ref:
Independent) 
      Partially Dependent 0.657 0.200 -1.380 0.167 0.362 1.192 
Totally Dependent 1.666 0.596 1.430 0.154 0.826 3.360 
       ASA Class (ref: Mild
Disturbance)  
      Life Threat 1.828 0.432 2.560 0.011* 1.151 2.905 
Moribund 0.689 0.460 -0.560 0.577 0.186 2.550 
       Race (ref: White) 
      Black 1.185 0.264 0.760 0.446 0.766 1.834 
Other 0.896 0.238 -0.410 0.679 0.533 1.507 
       Pre-operative Laboratory
Values 
      estimated glomerular 
filtration rate (eGFR) 0.998 0.002 -0.960 0.339 0.995 1.002 
Albumin 0.793 0.088 -2.090 0.037* 0.638 0.986 
Sodium 0.986 0.017 -0.840 0.401 0.953 1.019 
Platelet count 0.999 0.001 -1.990 0.047* 0.997 1.000 
White blood cell count 1.008 0.013 0.630 0.528 0.983 1.034 
Total bilirubin 0.993 0.048 -0.140 0.891 0.904 1.091 
PT INR 1.734 0.367 2.600 0.009* 1.145 2.624 
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       Emercency surgery 0.884 0.168 -0.650 0.518 0.609 1.284 
       Diabetic Status (ref: Non-
diabetic) 
      Insulin dependent 1.980 0.403 3.360 0.001* 1.329 2.951 
Non-insulin dependent 1.094 0.298 0.330 0.741 0.642 1.866 
       Surgery Type (ref: Open
Abdominal) 
      Cardiothorasic 0.992 0.375 -0.020 0.983 0.473 2.082 
General surgery 1.210 0.358 0.650 0.519 0.678 2.161 
Other surgery type-not 
specified 1.449 0.670 0.800 0.423 0.585 3.586 
Any lapararoscopic procedure 1.397 0.494 0.940 0.345 0.698 2.794 
Cholecystectomy 0.500 0.254 -1.360 0.172 0.185 1.353 
Hernia repair 0.732 0.246 -0.930 0.353 0.379 1.414 
       Post-Operative Variables 
      Pneumonia 0.977 0.492 -0.050 0.963 0.364 2.624 
Sepsis 2.641 0.618 4.150 <0.001** 1.670 4.177 
Time on Table 1.002 0.001 2.800 0.005* 1.001 1.004 
Time from operation to 
discharge 0.910 0.016 -5.460 <0.001** 0.880 0.941 
Acute or Progressive Renal 
Failure 2.028 0.673 2.130 0.033* 1.059 3.885 
Urinary Tract Infection 3.248 1.154 3.320 0.001* 1.619 6.516 
On Ventilator >48 hrs 0.692 0.195 -1.310 0.191 0.399 1.202 
Unplanned intubation 1.837 0.559 2.000 0.046* 1.012 3.333 
       Discharge Destination 
      Home 1.251 0.286 0.980 0.327 0.799 1.960 
Rehab 0.452 0.176 -2.040 0.041* 0.211 0.968 
Separate Acute Care 0.382 0.230 -1.600 0.110 0.117 1.244 
       Total Hospital Length of Stay 1.008 0.012 0.680 0.497 0.985 1.031 
_cons 2.340 5.784 0.340 0.731 0.018 297.365 
*P<0.01, **P<0.001 
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Table 12. Readmission Model Validation Summary 
Calibration  
     
Calibration -in-the-Large 0.0000 
  
0 
 
Calibration-in-the-Small 0.0007 
  
2.65% 
 Hosmer-Lemeshow Goodness-of-
fit  (chi^2 test) 9.40 p=0.310 
   
      
Discrimination 
     
AUROC 0.7541 
    
Sensitivity (cut-point=0.1425) 76.64% 
    
Specificity (cut-point=0.1425) 60.91% 
    Positive Predictive Value (cut-
point=0.1425) 27.66% 
    Negative Predictive Value (cut-
point=0.1425) 93.04% 
    
Correctly Classified 63.48% 
    
      
Out-of-Sample performance  
     
 
AUROC 
    
K-fold (k=10) method 0.7602 
    
Leave-one-out method 0.7541 
    
      
Overall Model Performance 
     
Brier Score 0.1186 
    
      
Cut-Point Performance  
     
Cutpoint Sensitivity Specificity Classified LR+ LR- 
0.143 76.64% 60.91% 63.48% 1.9607 0.3835 
0.150 75.00% 63.47% 65.35% 2.0531 0.3939 
0.160 72.95% 65.79% 66.96% 2.1323 0.4112 
0.170 70.49% 68.82% 69.10% 2.2612 0.4287 
0.180 66.39% 71.46% 70.64% 2.3266 0.4703 
0.190 62.70% 73.86% 72.04% 2.3989 0.5049 
0.200 61.48% 76.02% 73.65% 2.5635 0.5068 
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Figure 1. Mortality cohort. 
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Figure 2. Readmission cohort. 
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Figure 3. Decision curve analysis (mortality model). 
 
 
 
 
 
 
 
 
 
Figure 4. Decision curve analysis (readmission model). 
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Figure 5. Comparison of the mortality model to the MELD score (AUROC). 
 
 
 
 
 
Figure 6. Comparison of the readmission model to the MELD score (AUROC). 
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